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Protocol Synopsis 
PROTOCOL TITLE: Multicenter evaluation of the effectiveness of source control with 
daily chlorhexidine skin preparation in reducing nosocomial 
infections including MRSA and VRE 
PROTOCOL NUMBER : CI06-003 
SPONSOR: CDC and Sage Products, Inc.  
PRODUCT: 2% Chlorhexidine Gluconate Cloth and Comfort® Bath 
Washclothes 
PRIMARY OBJECTIVES: To determine if daily bathing with chlorhexidine impregnated 
washcloths will reduce the incidence of MRSA and VRE within an 
Intensive Care Unit (ICU) or ward setting. 
STUDY DESIGN: This is a cluster randomized, crossover, controlled trial with wards 
as the units of randomization. The trial will predominantly take 
take place in ICU’s but may include any acute care ward that has 
active surveillance for MRSA and or VRE in place (i.e., Bone 
Marrow transplant units, Oncology wards, etc.)  Units will be 
randomly assigned to utilize two bathing routines in a random 
order. Each bathing routine will be utilized on all admitted patients 
to the unit for a six month study period for a total study duration of 
12 months. The two bathing routines will include either the use of 
the Comfort® Bath Washcloth System (control) or the use of 2% 
Chlorhexidine Gluconate Cloth. Randomized units will either start 
with 2% Chlorhexidine Gluconate Cloth for six months and then 
switch to Comfort™ Bath Washcloth for the remaining six month 
period or the reverse order.  Data collection will include all 
surveillance and clinical cultures for MRSA and or VRE and all 
bloodstream infections. 
NUMBER OF SUBJECTS: Approximately 14 ICUs or acute care wards with 16,000 patients 
SUBJECT POPULATION: Males or Females, admitted to Intensive Care Units or acute care 
units 
NUMBER OF CENTERS: 7 centers 
DURATION OF SUBJECT 
PARTICIPATION: 
Typically 1-90 days, or the duration of patient’s ICU or unit 
admission 
TREATMENT: Daily bathing with either: 
1) Comfort® Bath Washcloth or 
2) 2% Chlorhexidine Gluconate Cloth 
ASSESSMENTS OF 
EFFICACY: 
The primary efficacy endpoint will be the reduction in MRSA 
incidence during those study periods where the 2% Chlorhexidine 
Gluconate Cloth was utilized. 
 
Additional study endpoints include overall incidence of nosocomial 
bloodstream infections, nosocomial MRSA bloodstream infections, 
incidence of VRE and rate of chlorhexidine resistance among study 
isolates. 
SAFETY: Safety will be assessed through the monitoring of adverse events 
associated with bathing products to include any skin rashes or 
hypersensitivity reactions. 
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2. Study Sites and Participants 
 
McGuire Veteran Affairs Medical Center 
Coordinating Center 
1201 Broad Rock Boulevard 
Richmond, Virginia 23249 
  Principal Investigator:   
Michael Climo 
Office: (804) 675 5018 
Cell: (804) 350-3487 
Fax: (804) 675 5437 
E-mail: Michael.climo@va.gov 
Co-investigator: 
 Edward Wong, M.D. 
 Office (804) 675-6792 
Fax: (804) 675 5437 
e-mail: Edward.wong@va.gov 
Co-investigator: 
 Jane Cecil, M.D. 
 Office: (804) 675-5470  
 Fax: (804) 675 5437 
e-mail: jane.cecil@va.gov 
  Research Coordinator 
 Christine Harper, RN 
 Office: (804) 675-5000 ext 3873 
 Fax: (804) 675 5437 
 e-mail christine.harper@va.gov 
Brigham and Women’s Hospital 
Harvard School of Medicine, Brigham and 
Women’s Hospital, Boston, Massachusetts 
 Co-investigator: 
 Deborah Yokoe, M.D., MPH 
181 Longwood Avenue, Channing 
Laboratory, Boston, MA 02115 
Office: (617) 525-2689 
Fax: (617) 731-1541 
e-mail: dyokoe@partners.org 
Johns Hopkins Hospital 
The Johns Hopkins University, Baltimore, MD 
  Co-investigator 
 Trish Perl, M.D., Msc 
 Office: (410) 955-8384 
 Fax: (410) 614-0888 
 Email: tperl@jhmi.edu 
  Study Coordinator  
Kathleen Speck 
Office: (410) 614-6206 
 Fax: (410) 614-0888 
 Email: kspeck2@jhmi.edu 
Memorial Sloan Kettering Cancer Center 
Memorial Sloan-Kettering Cancer Center 
New York, New York 
  Co-investigator: 
 Kent Sepkowitz, M.D. 
 e-mail: sepkowik@MSKCC.ORG 
Northwestern Memorial Hospital 
Northwestern University Feinberg School of 
Medicine, Chicago, Illinois 
  Co-investigator: 
 Maureen Bolon, M.D. 
 Office:  (312) 695-5059 
 Pager:  (312) 695-9873 
 Fax:  (312) 695-5088 
 Email:  m-bolon@northwestern.edu 
Co-investigator: 
 Gary Noskin, M.D. 
 Phone:  (312) 926-2729 
 Email:  gnoskin@northwestern.edu 
Research coordinator: 
 Farida Siddiqui 
 Office:  (312) 926-3693 
 Fax :     (312) 695-5088 
 Email:   f-siddiqui2@northwestern.edu 
University of Iowa Hospitals and Clinics  
University of Iowa College of Medicine,  
200 Hawkins Drive 
Iowa City, Iowa 52242-1081 
  Co investigator: 
Loreen Herwaldt, M.D. 
Daniel Diekema, M.D. 
Study coordinator: 
Melissa Ward 
Office: 319-356-0474 (Herwaldt) 
Fax:  319-353-8687 
 e-mail: loreen-herwaldt@uiowa.edu 
Barnes-Jewish Hospital 
Washington University School of Medicine  
St. Louis, Missouri 
  Co-investigator 
Dave Warren, M.D.  
Statistician 
  Andy Bush, PhD 
  University of Tennessee 
Economic Analysis  
  Todd Lee, M.D. 
  Northwestern University
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3. Introduction 
Healthcare-associated infections are a significant source of morbidity and mortality among 
patients treated in U.S. healthcare institutions.  One of the leading causes of nosocomial 
complications are bloodstream infections (BSIs) affecting between 87,500 and 350,000 patients 
annually with high attributable mortality and excess costs (1-6).  Preliminary investigations have 
indicated that the use of chlorhexidine bathing in routine care of patients within the ICU might 
reduce the incidence of methicillin-resistant S. aureus (MRSA), vancomycin-resistant 
enterococci (VRE) and nosocomial bacteremias.  This prospective multi-centered trial entitled 
“Multicenter evaluation of the effectiveness of source control with daily chlorhexidine skin 
preparation in reducing nosocomial infections including MRSA and VRE” is intended to 
determine the possible benefits of daily bathing with chlorhexidine.  This intervention aimed 
primarily at MRSA and VRE also has the potential to reduce other healthcare-associated 
infections including bacteremias and by its nature is a simple intervention that could be adopted 
by diverse US healthcare facilities. The trial will be co-supported by an industry sponsor, SAGE 
Products inc., the current manufacturers of a FDA approved washcloth product impregnated with 
2% chlorhexidine and the Centers for Disease Control and Prevention (CDC).   
 
4. Background and Significance 
 
Infections among patients admitted to the intensive care unit are a significant health care 
problem in all hospitals.  It is estimated that up to 20% of patients admitted to intensive care 
units develop an infection during their stay (1).  These infections lead to increased length of 
stays, increased morbidity and, most concerning, increased mortality.  Many of these infections 
are felt to be preventable and this has spurred recent interest in developing new strategies 
aimed at reducing their incidence. 
 
The majority of infections reported in the intensive care unit are due to urinary tract infections, 
ventilator associated pneumonia and bloodstream infections (2).  The majority are related to the 
presence of invasive devices (urinary catheters, mechanical ventilation and central venous 
catheters).  Mortality is highest for catheter associated bloodstream infections where the 
attributable mortality rate averages between 30-35% but can be as high as 69% (3, 4).  
Staphylococcus aureus is the second leading cause of bloodstream infections and the leading 
cause of ventilator associated pneumonia.  The increased incidence of MRSA is due in part to 
the rising prevalence of methicillin resistance among all staphylococcal isolates in the ICU.  The 
rising incidence of MRSA infections in the ICU is concerning due to high costs associated with 
their care and high mortality rates.  It is estimated that nosocomially acquired MRSA 
bloodstream infections are associated with a crude mortality of 22% and lead to $6,916 in 
excess costs (5).  In summary, infections due to Staphylococci including MRSA are the 
predominant nosocomially acquired complication in the intensive care unit.   
  
Another common multi-resistant pathogen seen within the intensive care unit is vancomycin 
resistant enteroccocus (VRE).  Between 1989 and 1993, the percentage of nosocomial 
enterococcal infections that were due to VRE increased from 0.3 to 7.9% (6).  The percentage 
has continued to rise. In 2003, VRE was the cause of 27.5% of enterococcal infections among 
ICU patients.  An increasing trend towards non-ICU patients having serious infections has been 
noted and most concerning there is a growing number of patients who have been documented to 
be colonized with both VRE and MRSA (7,8,46).   
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The increasing incidence of MRSA and VRE colonization and infection among ICU patients has 
been attributed to many factors including increased admission of patients already colonized with 
these pathogens to the ICU, prolonged carriage, poor compliance with handwashing and barrier 
precautions, delayed identification of colonized patients, and understaffing.  The rising 
prevalence of MRSA and VRE within US hospitals has prompted a contentious debate about the 
best approach to combat these serious healthcare associated pathogens.  Strategies that have 
been utilized to limit the spread of MRSA and VRE within ICU’s have included stricter attention 
to barrier precautions following identification of MRSA colonized patients as well as improved 
handwashing. One prominent strategy that has emerged as recommended by recent SHEA 
guidelines (9) suggests that hospitals should adopt more aggressive active surveillance culturing 
to identify unrecognized MRSA and VRE patients at the time of admission and periodically 
during their hospital stay.  Under this “search and isolate” strategy, proponents argue that once 
reservoirs of MRSA and VRE within the hospital are identified, nosocomial transmission can be 
effectively eliminated through the use of strict barrier precautions and hand hygiene for these 
previously unidentified patients.   
 
Despite the recommendations for the adoption of more widespread active surveillance culturing 
by the SHEA guidelines, most hospitals have not embraced this approach.  A recent survey from 
the IDSA Emerging Infections Network indicated that 86% of infectious disease consultants 
supported contact precautions to control MRSA, but less than 46% supported routine use of 
active surveillance cultures and less than 28% of hospitals employed MRSA surveillance 
cultures (10).  Reasons for this lack of enthusiasm for active surveillace culturing could include 
its attendant costs, the need for additional resources to maintain an active program, and the 
required high level of compliance with contact precautions and hand hygiene among healthcare 
personnel to make strict barrier precautions an effective containment strategy.   
 
The “search and isolate” strategy has additional flaws that could limit its overall effectiveness. 
First, to be effective, this strategy requires high levels of compliance with barrier precautions and 
handwashing to reduce horizontal transmission. As the literature has documented, both are 
difficult to achieve in real world settings.  Second the “search and isolate” strategy does little to 
eradicate colonization. In our study of MRSA patients admited to a combined MICU/CCU we 
found that 55% of identified MRSA colonized patients remained colonized for the duration of 
their ICU stay (11).  As long as patients remain colonized, the opportunity for transmission 
exists. We also know that colonization with MRSA is not a beign condition but associated with a 
risk for the development of serious infections during and after ICU admissions. Huang et al. 
followed ICU patients identified with MRSA for 18 months and found that 29% of these patients 
subsequently developed MRSA infection (12).  Additional reports have indicated that the risk of 
subsequent MRSA infection among colonized ICU patients is over 30% (13,14). Barrier 
precautions and proper handwashing do little to reduce this risk.  These considerations would 
suggest that additional stratgies may be needed to address prolonged skin carriage with MRSA 
and VRE as a strategy to reduce the risk for horizontal transmission as well as the potential to 
reduce subsequent infections among colonized patients.  
  
Previous studies in the prevention of catheter associated blood stream infections have indicated 
that there are a number of modifiable risk factors for catheter-associated bloodstream infection 
(15).  Most of these relate to proper sterile technique during the insertion and maintenance of 
central venous catheters (16). Proper site preparation with an effective skin disinfectant has 
been shown to be particularly important in reducing the incidence of subsequent catheter 
associated infections (17).  It is now recognized that chlorhexidine is superior to other agents in 
site preparation.  The use of chlorhexidine reduces residual skin organisms as well as inhibits 
their rebound growth and has been demonstrated to reduce CABSI in comparison to other skin 
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disinfectant products such as povidone-iodine.  CDC guidelines now recommend that the 
preferential use of chlorhexidine containing skin disinfectants be used for site preparation prior to 
insertion (17).   
 
The same properties that make chlorhexidine an effective agent in the prevention of CABSI have 
been utilized in selective settings to reduce the incidence of MRSA within the ICU.  
Chlorhexidene is an effective skin disinfectant that has been used successfully to eradicate 
MRSA skin colonization (18-20).  The reduction in skin colonization with MRSA (skin asepsis) is 
thought to lead to reduced risk for horizontal transmission of MRSA within the ICU environment.  
The use of chlorhexidine has been used successfully in the control of a number of MRSA 
outbreaks within the ICU setting  and in the community (21,22).  
 
The role of chlorhexidine in reducing nosocomial infections highlights the importance of skin 
asepsis in the intensive care environment.  Although the selective use of chlorhexidine as it 
relates to catheter site preparation and in the selective treatment of MRSA colonized patients 
during outbreaks has received preliminary study, there is little study of the potential utility of 
more wide scale use of chlorhexidine in daily bathing routines within the ICU and hospital.  With 
daily bathing with chlorhexidine, there is the potential to reduce a number of nosocomial 
infections, including CABSI by reducing bacterial burdens on the skin.  Reductions in resident 
bacteria on the skin could lead to reduced horizontal transmission of multiresistant bacterial 
pathogens and better outcomes following central line insertions.  Daily bathing to produce a 
state of skin asepsis as such is an attractive theorectical means to reduce nosocomial infections 
because it represents a simple intervention that could be applied universally with relatively little 
effort.   
 
The goal of the currently proposed study is to determine if universal use of a chlorhexidine-
based bathing system for unit patients will decrease skin bacterial burden and lead to decreased 
transmission to wardmates resulting in reductions in the incidence of MRSA and VRE.  
Secondarily, we hypothesize that reduced skin colonization with opportunistic bacterial 
pathogens will result in a reduction in the rate of catheter-associated bloodstream infections and 
overall bacteremias in comparison to regular bathing procedures.  
 
5. Preliminary Studies 
Chlorhexidine has long been recognized as an effective skin disinfectant. In use for over 30 
years, chlorhexidine gluconate is used extensively as a surgical scrub, hand wash and skin 
cleanser.  Chlorhexidine is rapidly active and has persistent activity for 2-5 days after application 
leading to excellent skin asepsis after use.  Its use has been shown to lead to reduced infection 
after surgery when used as a perioperative skin preparation (23-25).  The use of chlorhexidine in 
skin site preparation for central line insertion has been shown to lead to a two-fold reduction in 
the incidence of bloodstream infections in comparison to povodine-iodine (26,27).  As such, 
chlorhexidine is recommended as one of the preferred agents for skin site preparation in the 
current CDC guidelines for catheter site care and use (17).  Wider use of chlorhexidine in the 
prevention of nosocomial infections recently has included its incorporation into catheter material 
to prevent catheter associated bloodstream infections (28). Chlorhexidine has also been used 
during a number of nosocomial outbreaks of MRSA infections to provide skin asepsis and 
reduce horizontal transmission of MRSA between patients (21,22). 
  
The use of chlorhexidine as a potential agent in the control of MRSA within the hospital 
environment has been an area of research at the McGuire VAMC during previous funding cycles 
for the CDC Prevention Epicenters.  Preliminary work has examined the role of chlorhexidine in 
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reducing extra-nasal colonization with MRSA and the role of chlorhexidine at reducing MRSA 
transmission and infections within the intensive care unit.   
  
Beginning in July of 2003, the effectiveness of chlorhexidine in reducing extranasal colonization 
with MRSA following a hospital wide adoption of chlorhexidine bathing for all identified MRSA 
patients was examined at the McGuire VAMC in Richmond, Virginia.  Patients identified with 
MRSA were required to complete five days of daily bathing with chlorhexidine.  Serial cultures 
were taken and the extent of MRSA colonization followed over time.  Chlorhexidine was found to 
be a very effective agent in eradicating MRSA colonization. Table 1. presents the results of a 
cohort of patients that completed chlorhexidine bathing and had subsequent follow up cultures 
for up to three weeks.  
 
 
 
 
 
 
 
 
 
 
 
Based on these preliminary results, a focused intervention to determine if the more widescale 
use of chlorhexidine bathing could reduce the incidence of MRSA in high risk patients in the 
Intensive Care Unit was undertaken.  The study was a prospective evaluation of the selective 
use of mupirocin and chlorhexidine bathing for all patients identified with MRSA within a 
combined medical/coronary care unit.  During a nine month baseline period, the baseline 
prevalence and incidence of MRSA was determined through an active surveillance program that 
included nasal cultures for MRSA on admission to the unit and continued surveillance of 
identified MRSA patients with surveillance cultures taken three times a week.  No specific 
intervention other than the institution of contact precautions, barrier precautions and good hand 
hygiene for patients identified with MRSA was made during the baseline period.  During the 
planned nine month intervention period all patients identified with MRSA were prescribed 
mupirocin for intranasal application for four days and received daily bathing with chlorhexidine 
for five days. The study took place between January 2003 and August 2004.  The results of the 
study are presented in Table 2.  
 
Table 2. Effectiveness of selective chlorhexidine bathing on MRSA incidence in the ICU 
(McGuire VAMC 1/03- 8/04) 
Study Period Admissions Admission 
Prevalence  
Prevalence per 1000 
ICU pt days (range) 
Incidence per 
1000 pt ICU days 
(range) 
Incidence per 1000 
days at risk (range) 
Baseline 845 11.00 %  29.33 (15.67-56.91) 6.62 (2.92-17.85) 8.45 (3.38-20.98) 
Table 1. Effect of chlorhexidine bathing on extranasal MRSA 
colonization 
Site of MRSA 
Colonization 
Patients with 
MRSA+ 
Initial 
Cultures 
Patients 
with 
Follow up 
cultures 
Patients with 
MRSA- 
follow up 
cultures 
Percent 
cleared 
Extranasal     
   Axilla 16 (17%) 10 8 80% 
   Perineum 35 (37.2%) 23 18 78.3% 
   Wound 5 (5.3%) 3 3 100% 
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Intervention 736 9.38% 21.01 (7.20-32.03) 3.35 (0-8.04) 4.05 (0-10.91) 
p=0.048 
 
The study has several important findings. The overall incidence of MRSA decreased 48% during 
the intervention period with 21 new MRSA cases detected during the baseline period and only 
11 new MRSA cases during the intervention period. (Table 2).  This resulted in a statistically 
significant difference in the incidence density [new cases of MRSA per 1000 patient days at risk] 
of 8.45 vs 4.05, p=0.048.  Second, the prevalence of MRSA at unit admission was slightly lower 
in the intervention period and this was directly attributable to chlorhexidine bathing and 
intranasal mupirocin that occurred both within the hospital and on former ICU patients (Figure 1).  
20/31 (65%) patients admitted to the unit with a previous history of MRSA had received 
chlorhexidine bathing prior to their admission and had negative surveillance cultures at the time 
of admission. Third, during the baseline period the majority of patients identified with MRSA 
were colonized for the duration of their ICU stay (55%). During the intervention period the 
duration of colonization with MRSA was substantially reduced. There were no reported problems 
attributed to the use of chlorhexidine bathing during the intervention.  MRSA isolates collected 
during the study underwent susceptibility testing to chlorhexidine.  Over 200 isolates were tested 
and there was no documented resistance to chlorhexidine using a breakpoint for MIC90 of 4 
μg/ml.  There was no evidence of acquired resistance to chlorhexidine or changes in MICs 
among serial isolates collected from patients. 
 
 
 
In this study, the possible benefits of the addition of chlorhexidine bathing in an ICU with active 
surveillance culturing in place was studied.  As such this study attempted to quantify the 
additional benefits of eradication of MRSA colonization in reducing MRSA incidence.  The use of 
chlorhexidine bathing and mupirocin were a means to produce skin asepsis and eradicate a 
large reservoir of MRSA within the unit.  The study examined the use of chlorhexidine in 
selected patients, as only patients identified with MRSA were the only patients who received 
chlorhexidine bathing.  The study found this to be a very successful strategy resulting in a 48% 
decrease in the incidence of MRSA beyond that seen with active surveillance culturing alone.  
These results were striking as the study was not initiated as a result on any outbreak or 
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Figure 1.  MRSA Prevalence and Incidence following the introduction of 
chlorhexidine bathing for MRSA patients 
(1/2003-8/2004)
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abnormally high rate of MRSA within the study unit, but as a planned prospective analysis 
prompted by a change in hospital policy.  
 
These encouraging results led to a second pilot study. The second pilot study differed from the 
first in that all study ICU patients received chlorhexidine (universal bathing), not just the subset 
of patients identified as MRSA carriers by surveillance cultures. This study was a prospective, 
before-after, interventional design taking place within a combined medical/coronary care unit and 
surgical ICU that took place from January 20005 to December 2005.  During a six-month 
baseline period, patients received bathing as usual.  Baseline rates of MRSA prevalence and 
incidence were determined by ongoing surveillance that included admission cultures for MRSA, 
weekly prevalence culturing and clinical cultures.  During the planned six month intervention 
period, all patients admitted to the unit received daily bathing with chlorhexidine.  Bathing was in 
the form of a basin bed bath.  Approximately 4 ounces of 4% chlorhexidine solution was added 
to a basin filled with warm water. Patients were then bathed according to standard nursing 
protocols for bed baths with special care to avoid contact with mucous membranes and the 
eyes.  The results of the study were striking.  The overall incidence of MRSA decreased 45% in 
the two ICUs (Table 3).  The decrease in incidence was seen with similar rates of prevalence 
during both periods indicating a true decrease in incidence not related to burden of colonization 
within the units.  The overall incidence of nosocomial bacteremias decreased 25% from 8.8/1000 
patient days to 6.6/1000 patient days.   
 
Table 3. Effect of Daily Chlorhexidine Bathing among Patients Admitted to a combined 
CCU/MICU and SICU at the McGuire VAMC (1/05-12/05) 
 
Baseline Period 
(1/05-6/05) 
Intervention Period 
(7/05-12/05) 
MRSA cases (no of cases on admission) 55 39 
MRSA Prevalence (per 1000 patient days) 13.48 11.31 
Incident MRSA cases (n) 28 12 
Incidence Density (new cases per 1000 patient days) 8.27 4.57 
Incident Bacteremias (n) 36 23 
Bacteremia Incidence (new bacteremias per 1000 patient 
days) 8.8 6.6 
 
In 2005, three additional CDC Prevention Epicenters (Washington University, Memorial Sloan 
Kettering, and Johns Hopkins) also completed pilot studies of the effect of universal bathing with 
chlorhexidine in the ICU and its effect on the incidence of MRSA, VRE and nosocomial 
bacteremias. These three studies had a similar design to the study completed at McGuire.  All 
three studies were prospective, before-after, interventional designs.  Each had a six month 
baseline period followed by a six month intervention where all admitted patients to the study 
units received chlorhexidine bathing daily.  In addition to MRSA surveillance, surveillance for 
VRE was also completed in some units.  Again this surveillance included admission cultures for 
VRE as well as ongoing surveillance while patients were admitted to the study units. The intent 
of these pilot studies was to determine the possible impact of daily chlorhexidine bathing on the 
incidence of MRSA, VRE and nosocomial bacteremias.  These pilot studies were also designed 
to test the feasibility of a larger multi-center design and to independently confirm preliminary 
results seen at McGuire at other institutions.   
 
The results of preliminary data analysis are encouraging. Memorial Sloan Kettering has 
demonstrated a 67% decrease in the incidence of MRSA and a 50% reduction in the incidence 
of VRE following the introduction of universal bathing with chlorhexidine (Table 3).   
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At Johns Hopkins University, the pilot study was completed in two separate ICUs. The overall 
incidence of VRE decreased 41 % from 20.38 cases/1000 patient days to 12.06/1000 patient 
days. The overall incidence of incident bacteremias/fungemias decreased 44% from 2.74/1000 
patient days to 1.53/1000 patient days (Table 4).  More importantly, the reduction in bloodstream 
infections was noted among all organism types. Reductions were seen in the number of 
fungemias and bacteremias, including enterococci, gram positives, and gram negative 
organisms (Figure 2). 
 
 
 
In summary, several pilot studies completed within the CDC Prevention Epicenters between 
2002 and 2006 indicate that universal bathing with chlorhexidine may be a very effective 
modality to reduce the incidence of MRSA, VRE and nosocomial bacteremias.   
 
As encouraging as the data from the second pilot study may be, there are several 
methodological limitations.  First, the study was not designed as a multicenter randomized 
control trial.  Each participating center conducted the pilot study as a stand-alone project and 
while the same definitions and similar methodologies were used, they were not identical.  As an 
example, all of the studies have studied the use of chlorhexidine used in basin baths. Typically a 
four percent solution of chorhexidine was added to a basin filled with water and patients were 
bathed by nursing personnel in bed. This method of basin baths is often inefficient; results in 
varied concentrations of chlorhexidine and cannot be completed on all patients, particularly 
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Figure 2.  Reduction in Bacteremias and Fungemias Following the Use of 
Daily Chlorhexidine Bathing- Johns Hopkins University
Control Period (January-
June 2005)
Intervention Period (July-
December 2005)
Table 3. Effect of Daily Chlorhexidine Bathing among ICU Patients  
Memorial Sloan Kettering (1/05-12/05) 
 
Baseline 
(1/05-6/05) 
Intervention  
(7/05-12/05) 
MRSA Admission Prevalence 6.08%    7.10% 
MRSA Incidence (n) 15    4 
MRSA Incidence (cases per 100 patient days) 5.73    1.59 (p=0.024) 
VRE Admission Prevalence  17.63    14.52 
VRE Incidence (n)  33    17 
VRE Incidence (cases per 1000 patient days) 14.73    7.42 (p=0.020) 
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those with serious medical problems.  As such compliance with bathing reported during pilot 
studies ranged from 70-95%.  Secondly, the number of study patients from each institutions is 
small, and even if the results from individual institutions can be combined, there may be 
insufficient numbers (sample size and power) to detect a statistically significant reduction in 
BSIs.  These methodologic issues suggest the need for a larger multicenter trial and ideally, the 
use of a product that would allow for standardized concentrations of chlorhexidine.   
 
In 2002, SAGE Products, Inc., developed a new product to be used for bathing patients. Sage, 
inc. is a large supplier of healthcare products to hospitals including the Comfort Bath® washcloth 
system (see Appendix).  Many hospital systems use the Comfort Bath product that allows for 
simple bathing of patients without the need for soap, water or basins.  The Comfort Bath 
washcloth system contains eight pre-moistened washcloths that are used to wipe and cleanse 
each are of the body.  They are disposed of after use. The procedure requires no soap and 
water. In 2002 Sage developed a new washcloth impregnated with 2% chlorhexidine.  These 
washcloths reduce the number of microorganisms on the skin and deliver residual antimicrobial 
activity for a prolonged period of time. In the first pilot trial of the effectiveness of the new 
chlorhexidine impregnated washcloth, Vernon et al examined 1787 patients admitted to a 
medical intensive care unit from October 2002 to December 2003 (29).  They were able to 
document a reduction in the skin colonization with VRE for those cleansed with the new product 
as well as a 65% reduction in the incidence of VRE (26 per 1000 patient days to 9 per 1000 
patient days). Additionally they noted reductions in the level of environmental contamination and 
the level of contamination of healthcare worker’s hands with VRE.   This new product was well 
tolerated and resulted in higher compliance with daily bathing and also delivered standard 
concentrations of chlorhexidine. These data in combination with those previously generated in 
the CDC prevention Epicenters would indicate that this product would be an ideal candidate for 
further study of the effects of chlorhexidine bathing in a larger multicenter trial. 
 
6. Research Design and Methods 
 
6.1 Hypothesis:  
 
A change in the regular bathing procedures to utilize products containing chlorhexidine will 
result in a reduction in the number of colonizing bacteria, including MRSA and VRE, on the 
skin of patients.  Reduced colonization of the skin (skin asepsis) will lower the incidence of 
nosocomial transmission of bacteria in the ward and decrease incident cases of new 
bacteremias caused by these bacteria.   
 
6.2 Design:   
Prospective, cluster randomized, stratified, crossover trial of units. Units will serve as the as 
the units of randomization and as their own control.  Units will be stratified by the presence 
of active surveillance culturing for MRSA and/or VRE at the time of study entry.  
 
6.3 Study Setting:   
The study will take place in two or more units per participating hospital.  Approximately 14 
units will be enrolled.  Enrolled units will be predominantly intensive care units (ICUs) 
although additional units where active surveillance for MRSA and or VRE takes place will 
also be enrolled to include a Bone Marrow Transplant unit, a Burn unit and a Hematology 
Oncology ward. Study personnel will track blood culture data, patient-days, and MRSA and 
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VRE specific data per protocol.  Units must have pre-existing active surveillance for MRSA 
and/or VRE in place at the time units undergo randomization in order to participate.   
6.4 Participating Hospitals: 
 
McGuire Veteran Affairs Medical Center (Coordinating Center) 
Richmond, Virginia 
 Principal Investigator: Michael Climo 
 Co-Investigators: Edward Wong, Jane Cecil 
Johns Hopkins University 
Baltimore, Maryland 
 Co-investigator: Trish Perl 
Memorial Sloan Kettering 
New York, New York 
Co-investigator: Kent Sepkowitz 
Brigham and Women’s Hospital 
Boston, Massachusetts 
Co-investigator: Debbie Yokoe 
University of Iowa 
Iowa City, Iowa 
Co-investigator: Loreen Herwaldt 
Northwestern University 
Chicago, Illinois 
Co-investigator: Maureen Bolon 
Washington University 
St. Louis, Missouri 
Co-investigator: Dave Warren 
 
6.5 Intervention:  
Selected units will be randomized to start with either Comfort Bath wash clothes or new 
chlorhexidine containing wash clothes.  The unit of randomization will be a single unit.  The 
units will utilize the randomized bathing procedure (Comfort Bath washcloths or 
washclothes impregnated with 2 % chlorhexidene) for all patients admitted to the 
participating unit for a six month period of time and then switch to the alternative product for 
an additional six month period (figure 2).  The periods that utilize the regular Comfort Bath 
wash clothes (control periods) will be compared to the periods in which the washcloths 
impregnated with chlorhexidine (Intervention period) are used for each ward.  Patients will 
be bathed daily with data collection on the compliance with daily bathing.  Data collection 
during the study will include all positive blood cultures, patient days for study units as well 
as additional data on MRSA and/or VRE colonization and infection among admitted 
patients.   
 
Figure 3.  Randomization Sceme  
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6.6 Outcome measures:  
 
1.  Overall rate of nosocomial BSI with significant bacterial pathogens during the control 
period in comparison to the rate during the use of chlorhexidine bathing. 
 
A. Specific rates will include: 
 
1) Number of MRSA bacteremias per 1000 patient days 
 
2) Number of VRE bacteremias per 1000 patient days 
 
3) Total number of bacteremias for all significant bacterial and fungal 
pathogens per 1000 patient days 
 
4) Number of bacteremias or fungemias for individual pathogens per 1000 
patient days. 
 
B. Bacteremias will include only first significant bacteremia/fungemia for patients 
during each ICU or ward admission and will not include duplicate bacteremias 
during a single ICU or ward admission.  Significant bacteremias will also only 
include bacteremias with organisms not considered to be skin contaminants (see 
organism key Appendix B for definition) 
 
C. Due to the large number of patients involved in this study and its prolonged 
nature we have elected not to collect line days for each unit or to characterize 
bloodstream infections as catheter associated or not catheter associated.  Active 
surveillance of this nature is time consuming and unlikely to add additional 
information to the study as we are studying an intervention intended to reduce 
the overall rate of BSI within the study units.  As such the denominator for all 
calculations will be total patient days.  This is a reasonable surrogate measure of 
line days in the intensive care unit as up to 87% of all ICU associated BSI are 
catheter associated ().   
 
2. Overall rate of incident cases of MRSA/VRE colonization and infection (incidence 
density) in the baseline period in comparison to the rate during the use of 
chlorhexidine bathing.  Specific calculated rates will include: 
 
Presence of Active Surveillance
Randomization 
First Six Months  Second Six Months 
14 units
MRSA Only
VRE only 
MRSA and VRE 
Control
Control
Control
Control
Control
Control
Intervention
Intervention
Intervention
Intervention
Intervention
Intervention
Anticipated 
Number of Units 
4 
1 
1 
2 
4 
2 
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A. Number of new MRSA/VRE positive patients per total number of patients.  Monthly 
range and variance.   
 
B. Number of new MRSA/VRE positive patients per 1,000 patient days.  Monthly 
range and variance. 
 
C. Number of new MRSA/VRE positive patients per 1,000 eligible patient days.  
Monthly range and variance.  Eligible patient days are those days susceptible  
patients were at risk for acquisition of MRSA or VRE [Total patient days – total 
patient days for patients identified with MRSA or VRE] This denominator reflects 
the true incidence of colonization or infection.  
 
6.7 Data collection: 
  
6.71 Patient Specific Information:   
 
Each patient admitted to the study unit during the study periods will be recorded and 
assigned a specific study number. The dates of admission, dates of discharge, study 
unit will be recorded and used to calculate length of stay and to determine the 
incidence of nosocomial infections based on microbiological data.  Data entry will be 
entered into a password protected Access database. The Access database was 
developed during previous pilot work within the CDC prevention Epicenters (2003-
2006) and has been used extensively by four centers (Johns Hopkins, McGuire, 
Memorial Sloan Kettering and Washington University) during their single institution 
evaluation of the effectiveness of chlorhexidine bathing. (see Appendix A).  As with 
previous work completed within the CDC Epicenters, patient identifiers (in this case 
patient names and medical record number) will be removed from the database prior to 
submission to the coordinating center (McGuire). This data and research will not be 
used or disclosed to any persons or entity outside of the study institutions.  All data 
collection files will be password protected and stored on computers belonging to study 
investigators.  Personal health information will be maintained with the database during 
the collection of unit census data, microbiology data, and medical record review.  All 
patients will be assigned a study identification number that is unique to each 
institution.  Each participating institution will maintain a password protected code key 
file at their institution that will link study identifiers to patient identifiers.  This code key 
will be accessible only to study investigators and study staff.  Any hard copies of 
datasets will be stored in a locked filing cabinet.  After all data are collected, analyzed, 
and published, linkage between patients and their unique identifier will be destroyed, 
with the exception of data collected through Infection Control Departments as part of 
hospital operations.  Identified datasets related to infection control activities will be 
maintained at the primary institution according to hospital operations policy.   
   
6.72 MRSA Screening:  
 
Microbiological data on all MRSA surveillance performed within the study unit will be 
recorded for those units who have active surveillance in place.  Active surveillance will 
be defined as cultures for MRSA within 48 hours of admission and at least once 
weekly while admitted to the unit or at time of discharge.  Data entry will be entered 
into a password protected Access database. An incident case will be defined as any 
patient with a positive active surveillance or clinical culture > 48 hours after ICU 
admission in patients with either previous negative surveillance and clinical cultures or 
 Page16 
no previous history of MRSA.  Prevalent cases will be defined as any patient with 
positive active surveillance cultures or clinical cultures collected within 48 hours of 
admission. Weekly reports on compliance with admission surveillance cultures for all 
admitted patients will be monitored and reported during weekly teleconferences.   
 
6.73 VRE Screening:  
 
Microbiological data on all VRE surveillance performed within the study unit will be 
recorded for those units who have active surveillance in place.  Active surveillance will 
be defined as cultures for VRE within 48 hours of admission and at least once weekly 
while admitted to the unit or at time of discharge.  Data entry will be entered into a 
password protected Access database.  Incident and prevalent cases will follow the 
same definitions as above for MRSA patients.  Weekly reports on compliance with 
admission surveillance cultures for all admitted patients will be monitored and reported 
during weekly teleconferences.   
 
6.74 Clinical Culture Data:   
 
Microbiological data on all clinical cultures positive for MRSA or VRE will be entered 
into the Access database.  These data will be compiled with surveillance data in order 
to determine prevalence and incidence rates for MRSA and VRE.  
 
6.75 Blood culture data:  
 
Data on all positive blood cultures will be collected for significant bacterial/fungal 
pathogens if they occurred >48 hours after unit admission and within 48 hours of 
discharge from the study unit.  This will include all organisms with the exception of 
common skin contaminants and all coagulase negative staphylococci (see organism 
key Appendix B).  Data collected will be entered into a password protected Access 
database.  Incident bacteremias (or fungemias) will include only the first significant 
bacteremia with a significant bacterial or fungal organism during the unit admission 
and will not include duplicate organisms or subsequent infections as the primary aim 
of the study is to prevent incident cases.  
 
6.76 Compliance Monitoring:  
 
Confirmation of compliance with daily bathing will be collected by individual centers on 
a weekly basis during both the baseline and intervention periods.  Compliance 
monitoring will consist of monitoring the use of Comfort Bath washcloth packages and 
new washcloth packages impregnated with 2% chlorhexidine during the week and 
ensuring that adequate supplies exist. The total quantity of washcloth packages used 
during the week will be entered into a compliance monitoring worksheet. For the 
purposes of this study, use of one washcloth package will be considered receipt of 
one patient bath.  Oversight of the trial will not include direct observation of bathing.  
Previous work completed during pilot studies has indicated that the overwhelming 
majority of bathing occurs during the evening and late night shifts making it nearly 
impossible for research personnel to perform direct observation.  Since the Comfort 
Bath washcloth package is designed to complete one patient bath it is reasonable to 
assume that use of one product will represent receipt of one bath. At the time of data 
analysis, the use of Comfort Bath washcloth packages and washcloth packages 
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impregnated with 2% chlorhexidine will be compared to the number of patients in the 
study unit to determine the approximate compliance with bathing. 
 
6.77 Data Collection Forms 
 
All data will be entered at the participating site into an Access Database (see 
Appendix A)  Data will include basic demographic information on study patients as 
well as all culture information to include MRSA screening, VRE screening and blood 
culture data.  The database will be password protected at the site.  Definitions for all 
database fields are contained with in Appendix C.  Prior to submission to the 
coordinating center (McGuire), patient identifiers (name and medical record number) 
will be removed from the database. 
 
6.8 Trial Oversight:  
 
All principal investigators will serve on the steering committee for oversight of the trial.  All 
investigators have participated previously in weekly teleconferences to develop, implement, 
and analyze multicenter projects during previous CDC Prevention Epicenter Funding 
(1999-2006). Oversight of this trial will follow a similar design with weekly teleconferences 
of the steering committee. At that time there will be weekly discussions of the progress 
report, reporting of compliance with active surveillance, reporting of compliance with 
bathing, and any adverse reactions or other weekly problems.  
 
6.9 Statistical Analysis:  
 
The effect of daily bathing with chlorhexidine impregnated washcloths on incidence density 
of BSI, MRSA, and VRE incidence will be modeled by means of Generalized Estimating 
Equations (GEEs) under the Poisson distribution family.  Since each unit is observed twice 
under the study’s crossover design (once under the experimental and once under the 
control condition) and the targeted outcome is in the form of counts (here new cases or 
infections related to patient days of exposure), the GEE methodology is needed to model 
the count outcomes while accounting for the natural clustering effects induced by repeated 
observation of units.   
 
Our study design requires three separate analyses based upon the type of surveillance 
(MRSA only, VRE only, or both) employed by the units.  The analysis of BSI rates will use 
data from all units and will incorporate a three level fixed effect designating surveillance 
type.  The analyses of MRSA and VRE rates, respectively, will be based on only those 
units engaging in the corresponding type of surveillance.  In the latter analyses, a two level 
fixed effect for surveillance type will be incorporated (MRSA only versus both - or VRE only 
versus both).  
 
The fundamental model in these analyses will specify treatment, order of presentation, and 
type of surveillance fixed main effects.   Offsets in each model will be unit specific total 
patient days during the exposure periods.  Even though the study design targets minimizing 
order and type of surveillance effects and neither are expected to be present in any 
magnitude, their possible effects will incorporated for control purposes.  If either proves to 
be significant, their interactive effects with treatment will also be examined.  Such 
interactive effects are likewise not expected to be present. 
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All significance tests in these analyses will be conducted given two-tailed alpha of .05.  In 
addition, 95% confidence intervals estimating treatment and control rates as well as their 
ratio will be constructed.  It should be noted that in this study, there can be no missing data 
and consequently no missing data issues.  Analyses are planned to be conducted using the 
SAS System for Windows Genmod procedure (Version 9.1.3 or later). 
 
6.10 Power considerations: 
 
For power estimation, we have conservatively assumed that 12 units (4 units with both 
MRSA and VRE surveillance and 4 each using only one of the surveillance types) will be 
randomized under the study design.  Based upon our prior experience with admission rate, 
length of stay and observed infection rates in such units, we anticipate an average 
incidence density rate (new cases of MRSA per 1000 patient days) of 8 per 1000 patient 
days for MRSA, an average incidence density of 15 per 1000 days for VRE, and an 
average incidence of 8 1000 patient days for new nosocomial BSIs a during each unit’s 
control exposure.   
 
The following table shows power estimates corresponding to the test of treatment effect 
assuming six month exposures.  Power estimations are based on 1000 iterations of data 
randomly drawn from Poison distributions and analyzed via GEE for the treatment effect 
assessed.  Each cell in the table represents the power estimate for a specified combination 
of control rate and reduction rate due to treatment: 
 
Table of power estimates: 
 
Control Rate/1000 
Patient Days: 
BSI 
7 
BSI 
8 
BSI 
9 
MRSA 
7 
MRSA 
8 
MRSA 
9 
VRE 
14 
VRE 
15 
VRE 
16 
Reduction:          
30% 98% 99% 99% 94% 98% 98% 99% 99% 99% 
25% 94% 98% 99% 86% 88% 92% 98% 98% 99% 
 
 
Based upon prior research, we expect rate reductions to exceed 30%.  As the table shows, 
the study should have at least 95% power to detect 30% or greater rate reductions and 
85% or greater power to detect reductions as small as 25% in all three measured rate 
analyses.  Hence, the study will be more than adequately powered.  In fact, based on the 
number of enrolled units we estimate that we would be powered to detect a 30% reduction 
in MRSA, VRE and nosocomial bacteremias with incidence rates as low as 3.5/100 patient 
days, 4.5/100 patient days and 3.5/1000 patient days respectively during the control period.  
 
6.11 Economic Analysis 
  
In addition to understanding the effectiveness of the chlorhexidine impregnated washcloths 
it is important to estimate the cost-effectiveness of the interventions. We hypothesize that 
regular bathing utilizing products containing chlorhexidine will result in a reduction in the 
number of colonizing bacteria including MRSA and VRE on the skin of patients.  The 
reduced colonization of the skin will lower the incidence of nosocomial transmission of 
bacteria in the ward and decrease incident cases of new bacteremias caused by these 
bacteria.  Thus, the use of chlorhexidine impregnated washcloths may reduce the incidence 
of high cost MRSA and VRE infections in patients in intensive care units. Therefore it is 
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important to examine the cost-effectiveness of the use of chlorhexidine impregnated 
washcloths.   
  
There are three potential scenarios that could exist with the use of the chlorhexidine 
impregnated washcloths, of which one is unlikely based on pilot data. First, the washcloths 
could reduce the rate of nosocomial infections enough to offset the increased costs 
associated with the use of the chlorhexidine impregnated washcloths in which case the new 
intervention would be considered cost-savings. The second scenario is that the washcloths 
will decrease the rate of nosocomial infections but increase the total costs of care where it 
is then important to determine the cost-effectiveness (value) of the washcloths. The final 
scenario, which again is less likely based on the pilot data, would be where the washcloths 
are less effective than current bathing practices and more costly where the chlorhexidine 
impregnated washcloths would be dominated by the current bathing practices. A final 
scenario that is a possibility in cost-effectiveness analyses is where the chlorhexidine 
impregnated washcloths would be less effective and be associated with lower costs. This 
scenario occurs infrequently when the new technology, chlorhexidine impregnated 
washcloths in this case, cost more than the previous standard of care. 
 
To evaluate the cost-effectiveness of the chlorhexidine impregnated washcloths we will 
undertake two specific tasks: 
 
1. Compare the costs in the intervention and control arms of the trial; and 
 
2. Evaluate the cost-effectiveness of chlorhexidine impregnated washcloths compared 
to standard bathing practices by adapting a previously published model. 
 
For the first task we will compare the hospitalization costs between the two arms of the 
study. For each of the study arms, we will determine the length of stay for each 
hospitalization, the rate of colonization and the rate of nosocomial infections.  We will 
estimate the total cost of hospitalization for each individual included in the study. Because it 
is impractical to obtain billing data for each of the patients included in all of the institutions 
for the study we will estimate the hospitalization costs for individuals included in the trial. 
Using estimates reported in the literature or national averages may make the results more 
generalizable than relying on billing data from the eight institutions involved in the study. 
For the control arm, hospitalization costs will be a function of the length of stay, the average 
per diem cost for a hospitalization and the per diem costs associated with a nosocomial 
infection. 
 
 Total costscontrol = (LOSno infection * per diem costno infection) + (LOSinfection * per diem 
costinfection) 
 
For the treatment arm, the hospitalization costs will be similar to that of the controls with the 
incremental costs associated with chlorhexidine impregnated washcloths included in the 
equation. 
 
Total coststreatment = (LOSno infection * per diem costno infection) + (LOSinfection * per diem 
costinfection) + ((Cost chlorhexidine washcloths – cost Comfort Bath washcloths) * number of 
washcloths)) 
 
The per diem costs for infections will be estimated using the same procedure we have used 
in previous work (30).  For example, for VRE infections the per diem cost will be estimated 
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by combining total VRE cost estimates from Stosor and colleagues (31) ($83,897 – 
$56,707 = $27,190) with the length of stay data for VRE infections from Monteclavo et al. 
(32) (26.3 – 12.6 = 13.7 days) and adjusting to current year dollars ($27190/13.7 = $1984 
per day [1995 $] * Medical care component of CPI = cost in current year dollars). Similar 
methods will be used to estimate MRSA and other nosocomial infection costs based on 
previously published cost estimates (5). 
 
The difference in total hospital costs will be compared between the groups.  Because cost 
data typically does not conform to the necessary assumptions of normality when comparing 
means, the costs will be compared using non-parametric bootstrap techniques (33,34). The 
bootstrap methods, as described by Barber and Thompson (33) and Desgangné (34) allow 
for the estimation of differences in costs and the calculation of confidence intervals for the 
difference. The non-parametric approach makes no underlying assumptions about the 
distribution of the data and yet compares the arithmetic means and differences in arithmetic 
means. 
 
The bootstrap comparison will be done by sampling, with replacement, the costs from each 
of the groups until the original sample size in each arm is reached and calculating an 
average cost for each of these replicates. The difference in average costs will then be 
calculated between groups. This process will be repeated 1000 times to compare the 
average difference in hospitalization costs between control and intervention patients and 
the confidence interval surrounding the difference. 
 
The second task will involve comparing the cost-effectiveness of the intervention with the 
control in terms of cost per life year saved. To complete this task, we will modify a 
previously published model in which we evaluated the cost-effectiveness of screening 
programs for VRE (30).  The figures below show the structure of the model that will be 
easily adaptable to the comparison of the interventions rather than a screening program. To 
adapt the model, the two primary branches of the tree will be similar to the structure in the 
“No screen” branch in Figure 4 below. Both the intervention and control arms will have the 
same structure and the probabilities associated with the branches will come directly from 
the clinical trial. That is, the rate of colonization and infection for each arm of the decision 
tree will be based on the overall results from the clinical trial. The costs associated with 
each arm of the decision tree will be based on the hospitalization costs that were estimated 
above.  
 
In addition to the decision-tree portion of the model there is also a Markov component of 
the model that accounts for the benefit of reducing colonization and infections within a unit 
(figure 5).  This benefit is seen by reduced risk of nosocomial infections to patients in the 
unit that are not currently colonized.  The Markov process will be adapted to not only 
include the rate of transmission of VRE but of other nosocomial infections. 
 
The incremental cost-effectiveness ratio (ICER) will be calculated comparing the 
incremental costs and benefits associated with the intervention compared to the control. 
The formula for the ICER is: 
 
 ICER = (Costintervention – Costcontrol) / (Outcomeintervention – Outcomecontrol)  
 
The outcome that will be used in the cost-effectiveness analysis is life years. The base 
case will be the mortality rate observed in each arm of the study to determine the life years 
saved attributable to the intervention. However, because we may not have sufficient power 
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to compare mortality in the study, we will also use the estimated risk of mortality associated 
with nosocomial infections in a sensitivity analysis.  All analyses will be conducted from the 
perspective of the hospital.  Additionally, we will conduct a fully probabilistic analysis on the 
decision model.  Patients will move through the decision model based on the probability 
values at each of the nodes on the model.  We compared the surveillance strategies with a 
probabilistic analysis of the analytic decision model, which involves assigning a distribution 
to the probability values at certain nodes of the model rather than a single value (35-37).  
The probability for the value is then chosen randomly from this distribution through Monte 
Carlo simulation.  Using a probabilistic decision model incorporates uncertainty associated 
with the parameter estimates rather than relying on a single value to represent the 
estimate. 
 
Results will be reported as cost per life year saved associated with the intervention 
compared to the controls. We will compute 95% confidence intervals for the incremental 
cost-effectiveness ratio, plot the results on cost-effectiveness planes and produce cost-
effectiveness acceptability curves. In addition to the fully probabilistic analysis we will also 
conduct several sensitivity analyses. We will conduct one-way analyses on all variables 
included in the model. From the one-way analyses we will produce a funnel plot of the most 
influential parameters. We will also conduct two-way and multi-way sensitivity analyses on 
parameters that are thought to be correlated and co-vary with each other. 
 
 
 
Figure 4. Decision tree 
 
 Page22 
Model – Markov Process
No VRE
VRE Infection
Discharged Died
 
Figure 5. Markov process of the model 
 
6.12 Chlorhexidine Resistance 
 
Resistance to chlorhexidine is rare among both staphylococci and enterococci with 
reported MIC’s to chlorhexidine for staphylococci of 0.2 –3 μg/ml [0.00002-0.0003%] and 
for enterococci of 1-6 μg/ml [0.0004-0.0006%] (38-41).  Previous studies have also 
indicated that following serial passage of both staphylococci and enteroccci in the presence 
of chlorhexidine there are only minimal changes in MIC values and no evidence of reported 
high level resistance (38). Plasmid mediated resistance to antiseptics and disinfectants 
among staphylococci is well known. Most prevalent is the presence of the qacAB and 
qacCD  gene families which encode proton dependent export proteins that confer 
resistance to a wide variety of disinfectants.  Most prevalent among staphylococci is the 
qacA determinant found on the pSK1 family of conjugative plasmids that also typically 
encode resistance to a number of antimicrobials including ß-lactamase (42).   The 
presence of qacA results in substantial increases in MIC’s to quaternary ammonium 
compounds (QAC’s) but only a 2.5 fold increase in MIC’s to chlorhexidine (0.8 μg/ml to 2 
μg/ml), corresponding to concentrations well below those seen in commercial preparations 
of chlorhexidine (38).  Plasmid mediated resistance to chlorhexidine has not been 
described among enteroocci.  High level resistance to chlorhexidine among gram-negative 
bacterial organisms particularly Pseudomonas and Serratia has been reported (43-45).  
However many gram-negative organisms, fungal, and mycobacterial organisms remain 
susceptible to chlorhexidine. 
 
With such widespread use of chlorhexidine that is anticipated during this proposed trial, we 
will test isolates for chlorhexidine resistance.  Each participating center will ship isolates of 
staphylococci and enterococci collected within the study units to the coordinating center 
(McGuire VAMC).  We will adopt a sampling strategy for testing given the large number of 
units and patients involved in the study.  Each participating center will collect the first ten 
bacterial isolates (five MRSA and five VRE) from patients treated in the study during the 
calendar month and each month thereafter.  Culture specimens will be labeled with a 
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unique Study number identifier corresponding to the identifier in the database form and as 
such will contain no unique identifiers contained within the 18 HIPAA identifiers.  Over the 
twelve month duration of the study, we will collect 1,920 isolates of MRSA and VRE for 
testing.  All isolates will be tested for susceptibility to chlorhexidine.  MIC’s for chlorhexidine 
will be determined by an agar dilution method on Mueller-Hinton agar containing 
chlorhexidine diacetate (Sigma-Aldrich Inc., St. Louis, MO) in concentrations ranging from 1 
to 16 μg/ml (corresponding to 0.0001% to 0.0016%). Although no standard definition exists 
for resistance to chlorhexidine, previous studies have indicated that most isolates of MRSA 
and VRE have MIC’s <8 μg/ml (0.0008%).  For the purposes of this study, isolates with 
MIC>16 μg/ml will be considered resistant.  Susceptibility to chlorhexidine will be compared 
between periods where chlorhexidine impregnated washcloths were in use to determine if 
acquired resistance to chlorhexidine developed following its wide-scale introduction. 
Although the primary goal of this testing is to determine any level of resistance to 
chlorhexidine among clinical isolates of MRSA and VRE, this effort will represent the 
largest survey of clinical isolates of MRSA and VRE for susceptibility to chlorhexidine 
completed to date.   
 
7. Human Subjects Research Considerations 
 
7.1 Human Subjects Involvement and Characteristics  
This is a cluster randomized trial with an intervention that is based at the unit level. The 
“intervention” is examining two accepted bathing methods and the possible differences in 
the development of nosocomial infections based on the use of these products.  Because 
both SAGE washcloth products are FDA approved products, we will be seeking a waiver of 
documentation of informed consent.  All patients admitted to the units enrolled in this study 
will undergo bathing with two different bathing products (Comfort Bath Wash clothes or 
Wash clothes impregnated with 2% chlorhexidine) according to a randomization schedule.  
Both bathing products are FDA approved. The 2% chlorhexidine gluconate cloth is FDA 
approved as a patient perioperative skin preparation and for use to reduce bacteria that can 
potentially cause skin infection.  It is for this latter use that this study will use the product.  
Comfort Bath Wash clothes are used extensively as a basin-less form of patient bathing.  
The study will determine potential differences between the use of the two products and the 
incidence of MRSA, VRE and nosocomial bacteremias.  The proposed units are 
predominantly Intensive Care Units, Bone Marrow Transplant units and Hematology-
Oncology wards.  This indicates that the targeted patient population will be varied and will 
include a number of critically ill patients.  Intensive care units that will participate will include 
surgical intensive care units, medical intensive care units and cardiology intensive care 
units.  Patients in these units typically have a variety of medical conditions including post-
surgical problems, myocardial infarctions, coronary artery disease and a number of 
infectious and complex medical care requiring intensive unit care.  The expected age range 
of human subjects will be from 18-90 years of age as we will only be including units that 
serve adult populations. Both men and women will be included in the research. The 
proposed research will take place in six additional hospitals that include: Johns Hopkins 
University, Brigham and Women’s Hospital, Northwestern University, Washington 
University, Iowa University and Memorial Sloan Kettering.  
 
7.2 Sources of Materials  
Each patient admitted to study units during the study periods will be recorded and assigned 
a specific study number. The dates of admission, dates of discharge, study unit will be 
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recorded and used to calculate length of stay and to determine the incidence of nosocomial 
infections based on microbiological data.  Additional data that will be collected include birth 
decade, gender, date of initiation of contact precautions and all microbiologic data for 
positive surveillance or clinical cultures for MRSA or VRE. All positive blood cultures will 
also be recorded. Data entry will be entered into a password protected Access database. 
The Access database was developed during previous pilot work within the CDC prevention 
Epicenters (2003-2006) and has been used extensively by four centers (Johns Hopkins, 
McGuire, Memorrial Sloan Kettering and Washington University) during their single 
institution evaluation of the effectiveness of chlorhexidine bathing. (see Appendix A).  As 
with previous work completed within the CDC Epicenters, patient identifiers (in this case 
patient names and medical record number) will be removed from the database prior to 
submission to the coordinating center (McGuire). This data and research will not be used or 
disclosed to any persons or entity outside of the study institutions.  All data collection files 
will be password protected and stored on computers belonging to study investigators.  
Personal health information will be maintained with the database during the collection of 
unit census data, microbiology data, and medical record review.  All patients will be 
assigned a study identification number that is unique to each institution.  Each participating 
institution will maintain a password protected code key file at their institution that will link 
study identifiers to patient identifiers.  This code key will be accessible only to study 
investigators and study staff.  Any hard copies of datasets will be stored in a locked filing 
cabinet.  After all data are collected, analyzed, and published, linkage between patients and 
their unique identifier will be destroyed, with the exception of data collected through 
Infection Control Departments as part of hospital operations.  Identified datasets related to 
infection control activities will be maintained at the primary institution according to hospital 
operations policy.   
 
7.3 Waiver of Informed Consent 
This study will involve all adult patients admitted to the proposed study units. As such there 
is no recruitment strategy. It is intended to encompass all patients within the participating 
units. This study will be seeking waiver of informed consent in accordance with 45 CFR 
46.116(d) based on the following: 
 
1. The intended research presents no more than minimal risk to the patients.  The intent is 
to study the potential differences between two accepted bathing products for patients and 
to determine if there is the potential to reduce nosocomial infections.  Both products are 
FDA approved products and as such pose minimal risk to those patients involved.  Bathing 
with chlorhexidine is an accepted procedure within the hospital and is often applied to 
selected patient populations within the hospital including pre-operative patients.    
 
2. The activities within the proposal do not normally require informed consent. Bathing is an 
accepted practice within the hospital and does not require informed consent.  Surveillance 
cultures are normally done in the course of many hospital surveillance activities and the 
standard of care is to require only verbal permission prior to collection.   
 
3. This research could not be carried out without the waiver of consent.  Given the large 
number of patients involved, the requirement for individual written informed consent would 
make the research impossible. 
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4.  The waiver of informed consent will not adversely affect the rights and welfare of 
patients. The lack of informed consent will not ultimately affect the rights or welfare of the 
intended study participants. 
 
5. Whenever appropriate, subjects will be provided with additional pertinent information 
after their participation.  If there is any new information about the safety, utility or new 
research findings pertinent to the study participants, they will be immediately informed.  In 
the case of severely ill patients, surrogates will be informed as dictated by local institutional 
policies.  
 
7.4 Waiver of HIPAA Authorization 
 
This clinical research study will be seeking waiver of written HIPAA authorization based on 
the following: 
 
1. Use or disclosure of protected health information involves no more than minimal risk to 
the privacy of individuals. We will keep all data in a secure Access database that is 
password protected and accessible only to dedicated research personnel. Data entry for 
individual patients will be coded and not include patient’s full name or complete social 
security number.  All patients will be assigned a study identification number that is unique 
to each institution.  As with previous work completed within the CDC Epicenters, patient 
identifiers (in this case patient names and medical record number) will be removed from the 
database prior to submission to the coordinating center (McGuire).  Folllowing this de-
identification, the only protected health information contained within the database that will 
be forwarded to the coordinating center (McGuire) are the dates of admission and 
discharge dates from the study units.  None of the other protected health Information 
identifiers are contained within the database. Personal health information will be maintained 
with the database during the collection of unit census data, microbiology data, and medical 
record review.  Each participating institution will maintain a password protected code key 
file at their institution that will link study identifiers to patient identifiers.  This code key will 
be accessible only to study investigators and study staff.  Any hard copies of datasets will 
be stored in a locked filing cabinet.  All data collection files will be password protected and 
stored on computers belonging to study investigators.  After all data are collected, 
analyzed, and published, linkage between patients and their unique identifier will be 
destroyed, with the exception of data collected through Infection Control Departments as 
part of hospital operations.  Identified datasets related to infection control activities will be 
maintained at the primary institution according to hospital operations policy.  During the 
course of the study, information collected will not be disclosed to anyone other than the 
study personnel.  This data and research will not be used or disclosed to any persons or 
entity outside of the study institutions.   
 
2. The research cannot practicably be conducted without the waiver. Given the large 
number of involved patients, the research cannot be completed easily without the waiver. 
 
3. The research could not practicably be conducted without access to and use of the 
protected health information. Accurate determination of lengths of stays and total patient 
days for all involved study participants will require access to dates of admission and 
discharge (protected health information).  Without this information the research can not be 
practically conducted.  
 
7.5 Protection Against Risk. 
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The study site Principal Investigator is responsible for the preparation and submission of all 
documents and periodic reports required by the local IRB. All protocol amendments 
affecting the safety and welfare of study participants must be approved by the IRBs prior to 
implementation. All investigators and participating sites will be in full compliance with 
human subjects and HIPAA requirements. This study protocol will be submitted to the 
Centers for Disease Control for IRB approval and the CDC may defer to local center’s IRB 
for human subject research protection oversight. The sponsoring institution and 
participating institutions promise that the study will be conducted to good clinical practice 
guidelines, applicable laws and regulations, and will report to investigators and regulatory 
authorities significant findings that could affect the safety and well being of research 
subjects.  All study investigators and staff have been trained in human subjects research 
and HIPAA regulations.   
 
Monitoring of any unexpected adverse effects or serious adverse events related to study 
procedures will be the responsibility of local investigators and are to be reported 
immediately to the steering committee as well as appropriate IRB.  All unexpected adverse 
events and serious events are to be reported and sent to the steering committee at the 
coordinating center (McGuire) within five working days on the adverse event form (see 
Appendix H.) 
 
For the purposes of this research protocol unexpected adverse events and serious adverse 
events will be defined as follows: 
 
Unexpected adverse event:  Any adverse reaction or experience that is not listed in the 
current labeling for the drug product or investigators brochure. This includes events that 
may be symptomatically and pathophysiologically related to an event listed in the labeling, 
but differ from the event because of greater severity or specificity. Known adverse reactions 
to chlorhexidene containing topical products include irritation, sensitization, and generalized 
allergic reactions especially in the genital area.  Chlorhexidine should be kept out of the 
ears and eyes.  "Unexpected," as used in this definition, refers to an adverse experience 
that has not been previously observed (i.e., included in the labeling) rather than from the 
perspective of such experience not being anticipated from the pharmacological properties 
of the pharmaceutical product. 
 
Serious adverse drug event. Any adverse reaction or experience occurring at any dose that 
results in any of the following outcomes: Death, a life-threatening adverse reaction, 
inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant 
disability/incapacity, or a congenital anomaly/birth defect. Important medical events that 
may not result in death, be life-threatening, or require hospitalization may be considered a 
serious adverse drug experience when, based upon appropriate medical judgment, they 
may jeopardize the patient or subject and may require medical or surgical intervention to 
prevent one of the outcomes listed in this definition.  
 
 
7.6 Potential Risks  
This clinical research involves minimal risk to the patients involved since it involves only the 
use of two FDA approved bathing products.  Potential recognized risks of bathing with 
chlorhexidine include local skin irritation, allergic reaction and irritation of mucous 
membranes. Chlorhexidine is not to be used in children. This research only involves adult 
patients aged 18 years or older.  
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7.7 Potential Benefits Of The Proposed Research To The Subjects And Others  
The intent of this study is to demonstrate that the routine use of chlorhexidine in bathing 
practices will lead to reduced skin colonization with resistant bacteria including MRSA and 
VRE.  This reduction can lead to significant declines in the incidence of MRSA and VRE 
and nosocomial bacteremias.  Such reductions could have profound effects on associated 
health care costs and mortality.  Since the intervention that is proposed is of minimal risk to 
the involved patients the potential benefits far outweigh any potential risk to individual 
patients.  
7.8 Importance Of The Knowledge To Be Gained  
MRSA and VRE are serious nosocomial pathogens associated with high morbidity and 
mortality for involved patients. In addition, nosocomial bacteremias are the leading cause of 
death among intensive care unit patients.  Novel interventions that reduce these 
complications would greatly benefit large populations within our healthcare systems. If 
changes in bathing practices prove to be effective in reducing these complications, this 
would represent a simple intervention that could be applied broadly to all hospitals.  
 
7.9 Inclusion of Women and Minorities 
 
The proposed clinical research will involve all adult patients admitted to participating units.  
There will be no exclusion of any gender, racial or ethnic minority. Racial or ethnic origin of 
patients in previous pilot studies completed to date was not accurately determined (this 
information was not collected).  This does not compromise the scientific objectives of the 
research, since the proposed intervention it is to be applied universally and race, ethnic 
origin and gender have no bearing on the intended effect.  Although exact demographics 
for the targeted study populations are not readily available, we have estimated the 
distribution of gender and racial and ethnic groups to be enrolled based on prior studies 
done in the ICU environment. 
 
7.10 Inclusion of Children 
This clinical research will involve the enrollment of children. However it will only involve 
children from the age of 18-20 and as dictated by local policies for admission to the 
participating units. All of the proposed study units currently only admit adult patients.  For 
most of the participating units this includes patients >18 years of age. Since the definition of 
children for the purpose of this application include any patient < 21 years of age, we will be 
enrolling children. 
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Appendix A.  Example of Access Database Data Entry Forms 
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Apppendix B. List of Microbiologic Classification of Blood Stream Infections 
 
0
. 
NO GROWTH/ NEGATIVE 37. Corynebacterium jeikeium 74. Other (not listed elsewhere)               
1.  Achromobacter species 38. Corynebacterium, others 75. Pasteurella multocida                      
2.  Acinetobacter baumannii 39. Cryptococcus neoformans 76. Peptostreptococcus species 
3.  Acinetobacter calcoaceticus 40. Diphtheroids 77. Porphyromonas species 
4.  Acinetobacter lwoffii 41. Enterobacter aerogenes 78. Prevotella species                          
5.  Acinetobacter, others 42. Enterobacter cloacae 79. Propionibacterium species                 
6.  Actinomyces species 43. Enterobacter, others 80. Proteus mirabilis                           
7.  Aeromonas species 44. Enterococcus faecalis (vanco-
sensitive) 
81. Proteus vulgaris                            
8.  Alcaligenes species 45. Enterococcus faecalis (vanco-
resistant) 
82. Proteus, others                             
9.  Aspergillus species 46. Enterococcus faecium (vanco-
sensitive) 
83. Providencia species                         
10. Bacillus anthracis 47. Enterococcus faecium (vanco- 
resistant) 
84. Pseudomonas aeruginosa                 
11. Bacillus cereus 48. Enterococcus gallinarum 85. Pseudomonas, others                        
12. Bacillus subtilis 49. Enterococcus, others 86. Serratia marcescens                        
13. Bacillus, others 50. Escherichia coli 87. Serratia, others                            
14. Bacteroides fragilis 51. Flavobacterium species 88. Sporothrix schenckii                        
15. Bacteroides, others 52. Fungus 89. Staphylococcus aureus 
(methicillin-sensitive)                      
16. Blastomyces dermatitidis 53. Fusarium species 90. Staphylococcus aureus 
(methicillin-resistant) 
17. Branhamella catarrhalis 54. Fusobacterium species 91.
Staphylococcus capitis                   
18. Burkholderia cepacia 55. Gram-negative cocci unspecified            92. Staphylococcus coagulase 
negative           
19. Campylobacter species 56. Gram-negative rod unspecified              93. Staphylococcus 
epidermidis                  
20. Candida albicans 57. Gram-positive cocci unspecified            94. Staphylococcus 
haemolyticus                 
21. Candida glabrata 58. Gram-positive rod unspecified               95. Staphylococcus hominis                
22. Candida krusei 59. Haemophilus species                         96. Staphylococcus 
saprophiticus                
23. Candida lusitaniae 60. Histoplasma capsulatum                      97. Staphylococcus warneri                 
24. Candida parapsilosis 61. Klebsiella oxytoca                          98.
Staphylococcus, others                   
25. Candida tropicalis 62. Klebsiella pneumoniae                       99. Stenotrophomonas 
maltophilia                
26. Candida, others 63. Klebsiella, others                          100 Streptococcus group A 
(pyogenes)            
27. Citrobacter diversus 64. Lactobacillus species  101 Streptococcus group B 
(agalactiae)          
28. Citrobacter freundii 65. Listeria monocytogenes                      102 Streptococcus group D 
(bovis)               
29. Citrobacter koseri 66. Malassezia furfur                           103 Streptococcus pneumoniae 
30. Citrobacter, others 67. Microccoccus species                        104 Streptococcus viridans  
31. Clostridium difficile 68. Moraxella catarrhalis                       105 Streptococcus, alpha hem  
32. Clostridium perfringens 69. Morganella morganii                         106 Streptococcus, beta hem  
33. Clostridium, others 70. Neisseria gonorrhoeae 107 Streptococcus, others  
34. Coagulase negative staph 
(CNS) 
71. Neisseria meningiditis                           108 Torulopsis glabrata 
35. Coccidioides immitis 72. Neisseria, others 109 Yeast 
36. Corynebacterium group G-2 73. Nocardia species   
 
Note: Underlined organisms represent common skin contaminants for the purpose of assigning 
a BSI classification. Organisms in bold represent coagulase-negative staphylococcus species 
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Appendix C. Definitions of all Entry fields in Access Database 
 
Demographics Form 
 
1. Epicenter:  Drop list for participating centers in study 
 
2. Start Date:  Starting date of study period 
 
3. End Date:  Last date of study period 
 
4. Study ID: sequential ID number given to study patients 
 
5. MRN: Medical record of study patient used during data entry for tracking and 
accuracy.  Field is removed prior to data submission to coordinating center 
 
6. Last Name: Last name of study patient used during data entry for tracking and 
accuracy.  Field is removed prior to data submission to coordinating center 
 
7. First name: First name of study patient used during data entry for tracking and 
accuracy.  Field is removed prior to data submission to coordinating center 
 
8. Gender:  Gender of study participant 
 
9. First MRSA Institutional Culture Date: Date of the first recorded positive culture for 
MRSA at the institution for the study participant 
 
10. First VRE Institutional Culture Date: Date of the first recorded positive culture for 
VRE at the institution for the study participant 
 
11. Age at First Unit Admit:  Age of the study participant at the time of unit admission.  
Age is chosen from drop down list that is listed in decades; 1) <18, 2) 18-35, 3) 36-45, 
4) 46-55, 5) 56-65, 6) 66-75, 7) 76-85, and 8) >85. 
 
Unit Subform 
 
12.   UnitID:  Numbering system for ICU admissions, each admission is given a unique unit 
ID number,  all study ID are patient specific and thus each study ID may have multiple 
unit ID numbers.  Autonumbered on Dataview sheet. 
 
13.   Unit name:  Name of study unit, up to two units in study per participating institution 
 
14. Unit Admit Date:  Date of admission to study unit 
 
15.   Unit Discharge date:  Date of discharge from study unit 
 
16.   Study ID: Sequential ID number given to study patients 
 
17. Precautions on Admit:  Was patient placed on contact precautions on admission, (yes 
or no, checkbox) 
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18. Cultures Prior to Unit Admission: Were there cultures for MRSA or VRE present prior 
to admission to study unit (present or none)? Present prompts entry into Pre-Admit 
Cultures subform 
 
19. Cultures During to Unit Admission:  Were there any cultures taken during study unit 
admission (none or present)? Cultures include any cultures positive for MRSA, VRE and 
all positive blood cultures. Present prompts entry into Cultures subform 
 
 
Pre-Admit culture form 
 
 
20. Specimen Site: Site of most recent MRSA or VRE culture prior to admission 
 
21. Specimen__Date:  Date of most recent MRSA or VRE culture prior to admission 
 
22. MRSA Result:  Result of most recent MRSA culture prior to admission (yes, no, not 
eval) 
 
23. VRE Result  Result of most recent VRE culture prior to admission (yes, no, not eval) 
 
24. Organism:  MRSA or VRE, on this form should only reflect results of MRSA and VRE 
culturing prior to admission. 
 
25. StudyID:  Sequential ID number given to study patients generated on demographics 
form. 
 
Cultures subform 
 
26. Specimen Site: Site of MRSA or VRE culture during study unit admission.  Data on all 
blood cultures is also entered into this field by selecting blood culture as specimen site. 
 
27. Specimen__Date:  Date of MRSA or VRE culture during study unit admission 
 
28. MRSA Result:  Result of MRSA culture during study unit admission (yes, no, not eval) 
 
29. VRE Result  Result of VRE culture during study unit admission (yes, no, not eval) 
 
30. Organism:  MRSA or VRE, on this form should only reflect results of MRSA and VRE 
culturing during study unit admission. 
 
31. StudyID:  Sequential ID number given to study patients generated on demographics 
form. 
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Appendix D.  SAGE Products, Inc. Comfort Bath® Product Brochure 
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Appendix E.  SAGE Products, Inc. Chlorhexidine Impregnated Washcloth Product Brochure 
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Appendix F. MSDS - Comfort Bath® Wash cloth  
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Appendix G.  MSDS - 2% Chlorhexidine Gluconate Cloth 
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 ADVERSE EVENT SUBMISSION FORM 
Date:  
Principal Investigator:  Climo, Michael 
Protocol#:  CI06-003 
Protocol Title:  Multicenter Evaluation of The Effectiveness of Source Control With Daily Chlorhexidine Skin 
Preparation in Reducing Nosocomial Infections Including MRSA and VRE 
 
Sponsor:  SAGE Products, Inc., and Center for Disease Control and Prevention 
Research Coordinator(s): 
 
Phone: 
 
Fax: 
 
 
Report Type:   Initial     Follow-up 
Subject Identifier # (study ID number, do not list medical record number or other personal identifier): 
AE Date:   
AE Description (brief):   
 
 
 
 
 
 
 
 
 
Is the adverse event a previously described complication that is listed in the “Risk” section of the Investigator’s 
Brochure   Yes     No 
 
This is a (an):  
 
 Unanticipated/Unexpected Event  
(Any untoward event that is not identified with the 
current investigator brochure or study protocol) 
 
 Serious Adverse Event  
(Any untoward medical occurrence that results in 
death, is life-threatening, requires patient 
hospitalization, prolongs existing hospitalization, 
results in persistent or significant 
disability/incapacity, or is a congenital 
abnormality) 
 
The opinion of the Principal Investigator is that the 
relationship of the research procedure is: 
 
Unrelated 
Probably not related 
Possibly related 
Probably related 
Related 
Other:       
 
 
 
The Principal Investigator must promptly report to the IRB, in writing, any unanticipated side effects, hazards, 
or other problems involving risks to subjects or others.   Promptly report all adverse events considered to be 
related to research procedures to the Steering Committee. 
 
________________________________________          _________________ 
INVESTIGATOR SIGNATURE          DATE 
(Sub-investigator may sign if the investigator is unavailable (i.e. out of the country) 
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Protocol Synopsis 
PROTOCOL TITLE: Multicenter evaluation of the effectiveness of source control with 
daily chlorhexidine skin preparation in reducing nosocomial 
infections including MRSA and VRE 
PROTOCOL NUMBER : CI06-003 
SPONSOR: CDC and Sage Products, Inc.  
PRODUCT: 2% Chlorhexidine Gluconate Cloth and Comfort® Bath 
Washclothes 
PRIMARY OBJECTIVES: To determine if daily bathing with chlorhexidine impregnated 
washcloths will reduce the incidence of MRSA and VRE within an 
Intensive Care Unit (ICU) or ward setting. 
STUDY DESIGN: This is a cluster randomized, crossover-controlled trial with wards 
as the units of randomization. The trial will predominantly take 
place in ICU’s but may include any acute care ward that has active 
surveillance for MRSA and or VRE in place (i.e., Bone Marrow 
transplant units, Oncology wards, etc.)  Units will be randomly 
assigned to utilize two bathing routines in a random order. Each 
bathing routine will be utilized on all admitted patients to the unit 
for a six month study period for a total study duration of 12 
months. The two bathing routines will include either the use of the 
Comfort® Bath Washcloth System (control) or the use of 2% 
Chlorhexidine Gluconate Cloth. Randomized units will either start 
with 2% Chlorhexidine Gluconate Cloth for six months and then 
switch to Comfort™ Bath Washcloth for the remaining six month 
period or the reverse order.  Data collection will include all 
surveillance and clinical cultures for MRSA and or VRE and all 
bloodstream infections. 
NUMBER OF SUBJECTS: Approximately 14 ICUs or acute care wards with 16,000 patients 
SUBJECT POPULATION: Males or Females, admitted to Intensive Care Units or acute care 
units 
NUMBER OF CENTERS: 7 centers 
DURATION OF SUBJECT 
PARTICIPATION: 
Typically 1-90 days, or the duration of patient’s ICU or unit 
admission 
TREATMENT: Daily bathing with either: 
1) Comfort® Bath Washcloth or 
2) 2% Chlorhexidine Gluconate Cloth 
ASSESSMENTS OF 
EFFICACY: 
The primary efficacy endpoint will be the reduction in MRSA 
incidence during those study periods where the 2% Chlorhexidine 
Gluconate Cloth was utilized. 
 
Additional study endpoints include overall incidence of nosocomial 
bloodstream infections, nosocomial MRSA bloodstream infections, 
incidence of VRE and rate of chlorhexidine resistance among study 
isolates. 
SAFETY: Safety will be assessed through the monitoring of adverse events 
associated with bathing products to include any skin rashes or 
hypersensitivity reactions. 
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2. Study Sites and Participants 
 
McGuire Veteran Affairs Medical Center 
Coordinating Center 
1201 Broad Rock Boulevard 
Richmond, Virginia 23249 
  Principal Investigator:   
Michael Climo 
Office: (804) 675 5018 
Cell: (804) 350-3487 
Fax: (804) 675 5437 
E-mail: Michael.climo@va.gov 
Co-investigator: 
 Edward Wong, M.D. 
 Office (804) 675-6792 
Fax: (804) 675 5437 
e-mail: Edward.wong@va.gov 
Co-investigator: 
 Jane Cecil, M.D. 
 Office: (804) 675-5470  
 Fax: (804) 675 5437 
e-mail: jane.cecil@va.gov 
  Research Coordinator 
 Christine Harper, RN 
 Office: (804) 675-5000 ext 3873 
 Fax: (804) 675 5437 
 e-mail christine.harper@va.gov 
Brigham and Women’s Hospital 
Harvard School of Medicine, Brigham and 
Women’s Hospital, Boston, Massachusetts 
 Co-investigator: 
 Deborah Yokoe, M.D., MPH 
181 Longwood Avenue, Channing 
Laboratory, Boston, MA 02115 
Office: (617) 525-2689 
Fax: (617) 731-1541 
e-mail: dyokoe@partners.org 
Johns Hopkins Hospital 
The Johns Hopkins University, Baltimore, MD 
  Co-investigator 
 Trish Perl, M.D., Msc 
 Office: (410) 955-8384 
 Fax: (410) 614-0888 
 Email: tperl@jhmi.edu 
  Study Coordinator  
Kathleen Speck 
Office: (410) 614-6206 
 Fax: (410) 614-0888 
 Email: kspeck2@jhmi.edu 
Memorial Sloan Kettering Cancer Center 
Memorial Sloan-Kettering Cancer Center 
New York, New York 
  Co-investigator: 
 Kent Sepkowitz, M.D. 
 e-mail: sepkowik@MSKCC.ORG 
Northwestern Memorial Hospital 
Northwestern University Feinberg School of 
Medicine, Chicago, Illinois 
  Co-investigator: 
 Maureen Bolon, M.D. 
 Office:  (312) 695-5059 
 Pager:  (312) 695-9873 
 Fax:  (312) 695-5088 
 Email:  m-bolon@northwestern.edu 
Co-investigator: 
 Gary Noskin, M.D. 
 Phone:  (312) 926-2729 
 Email:  gnoskin@northwestern.edu 
Research coordinator: 
 Farida Siddiqui 
 Office:  (312) 926-3693 
 Fax :     (312) 695-5088 
 Email:   f-siddiqui2@northwestern.edu 
University of Iowa Hospitals and Clinics  
University of Iowa College of Medicine,  
200 Hawkins Drive 
Iowa City, Iowa 52242-1081 
  Co investigator: 
Loreen Herwaldt, M.D. 
Daniel Diekema, M.D. 
Study coordinator: 
Melissa Ward 
Office: 319-356-0474 (Herwaldt) 
Fax:  319-353-8687 
 e-mail: loreen-herwaldt@uiowa.edu 
Barnes-Jewish Hospital 
Washington University School of Medicine  
St. Louis, Missouri 
  Co-investigator 
Dave Warren, M.D.  
Statistician 
  Andy Bush, PhD 
  University of Tennessee 
Economic Analysis  
  Todd Lee, M.D. 
  Northwestern University
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3. Introduction 
Healthcare-associated infections are a significant source of morbidity and mortality among 
patients treated in U.S. healthcare institutions.  One of the leading causes of nosocomial 
complications are bloodstream infections (BSIs) affecting between 87,500 and 350,000 patients 
annually with high attributable mortality and excess costs (1-6).  Preliminary investigations have 
indicated that the use of chlorhexidine bathing in routine care of patients within the ICU might 
reduce the incidence of methicillin-resistant S. aureus (MRSA), vancomycin-resistant 
enterococci (VRE) and nosocomial bacteremias.  This prospective multi-centered trial entitled 
“Multicenter evaluation of the effectiveness of source control with daily chlorhexidine skin 
preparation in reducing nosocomial infections including MRSA and VRE” is intended to 
determine the possible benefits of daily bathing with chlorhexidine.  This intervention aimed 
primarily at MRSA and VRE also has the potential to reduce other healthcare-associated 
infections including bacteremias and by its nature is a simple intervention that could be adopted 
by diverse US healthcare facilities. The trial will be co-supported by an industry sponsor, SAGE 
Products inc., the current manufacturers of a FDA approved washcloth product impregnated with 
2% chlorhexidine and the Centers for Disease Control and Prevention (CDC).   
 
4. Background and Significance 
 
Infections among patients admitted to the intensive care unit are a significant health care 
problem in all hospitals.  It is estimated that up to 20% of patients admitted to intensive care 
units develop an infection during their stay (1).  These infections lead to increased length of 
stays, increased morbidity and, most concerning, increased mortality.  Many of these infections 
are felt to be preventable and this has spurred recent interest in developing new strategies 
aimed at reducing their incidence. 
 
The majority of infections reported in the intensive care unit are due to urinary tract infections, 
ventilator associated pneumonia and bloodstream infections (2).  The majority are related to the 
presence of invasive devices (urinary catheters, mechanical ventilation and central venous 
catheters).  Mortality is highest for catheter associated bloodstream infections where the 
attributable mortality rate averages between 30-35% but can be as high as 69% (3, 4).  
Staphylococcus aureus is the second leading cause of bloodstream infections and the leading 
cause of ventilator associated pneumonia.  The increased incidence of MRSA is due in part to 
the rising prevalence of methicillin resistance among all staphylococcal isolates in the ICU.  The 
rising incidence of MRSA infections in the ICU is concerning due to high costs associated with 
their care and high mortality rates.  It is estimated that nosocomially acquired MRSA 
bloodstream infections are associated with a crude mortality of 22% and lead to $6,916 in 
excess costs (5).  In summary, infections due to Staphylococci including MRSA are the 
predominant nosocomially acquired complication in the intensive care unit.   
  
Another common multi-resistant pathogen seen within the intensive care unit is vancomycin 
resistant enterococcus (VRE).  Between 1989 and 1993, the percentage of nosocomial 
enterococcal infections that were due to VRE increased from 0.3 to 7.9% (6).  The percentage 
has continued to rise. In 2003, VRE was the cause of 27.5% of enterococcal infections among 
ICU patients.  An increasing trend towards non-ICU patients having serious infections has been 
noted and most concerning there is a growing number of patients who have been documented to 
be colonized with both VRE and MRSA (7,8,46).   
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The increasing incidence of MRSA and VRE colonization and infection among ICU patients has 
been attributed to many factors including increased admission of patients already colonized with 
these pathogens to the ICU, prolonged carriage, poor compliance with handwashing and barrier 
precautions, delayed identification of colonized patients, and understaffing.  The rising 
prevalence of MRSA and VRE within US hospitals has prompted a contentious debate about the 
best approach to combat these serious healthcare associated pathogens.  Strategies that have 
been utilized to limit the spread of MRSA and VRE within ICU’s have included stricter attention 
to barrier precautions following identification of MRSA colonized patients as well as improved 
handwashing. One prominent strategy that has emerged as recommended by recent SHEA 
guidelines (9) suggests that hospitals should adopt more aggressive active surveillance culturing 
to identify unrecognized MRSA and VRE patients at the time of admission and periodically 
during their hospital stay.  Under this “search and isolate” strategy, proponents argue that once 
reservoirs of MRSA and VRE within the hospital are identified, nosocomial transmission can be 
effectively eliminated through the use of strict barrier precautions and hand hygiene for these 
previously unidentified patients.   
 
Despite the recommendations for the adoption of more widespread active surveillance culturing 
by the SHEA guidelines, most hospitals have not embraced this approach.  A recent survey from 
the IDSA Emerging Infections Network indicated that 86% of infectious disease consultants 
supported contact precautions to control MRSA, but less than 46% supported routine use of 
active surveillance cultures and less than 28% of hospitals employed MRSA surveillance 
cultures (10).  Reasons for this lack of enthusiasm for active surveillace culturing could include 
its attendant costs, the need for additional resources to maintain an active program, and the 
required high level of compliance with contact precautions and hand hygiene among healthcare 
personnel to make strict barrier precautions an effective containment strategy.   
 
The “search and isolate” strategy has additional flaws that could limit its overall effectiveness. 
First, to be effective, this strategy requires high levels of compliance with barrier precautions and 
handwashing to reduce horizontal transmission. As the literature has documented, both are 
difficult to achieve in real world settings.  Second the “search and isolate” strategy does little to 
eradicate colonization. In our study of MRSA patients admited to a combined MICU/CCU we 
found that 55% of identified MRSA colonized patients remained colonized for the duration of 
their ICU stay (11).  As long as patients remain colonized, the opportunity for transmission 
exists. We also know that colonization with MRSA is not a beign condition but associated with a 
risk for the development of serious infections during and after ICU admissions. Huang et al. 
followed ICU patients identified with MRSA for 18 months and found that 29% of these patients 
subsequently developed MRSA infection (12).  Additional reports have indicated that the risk of 
subsequent MRSA infection among colonized ICU patients is over 30% (13,14). Barrier 
precautions and proper handwashing do little to reduce this risk.  These considerations would 
suggest that additional stratgies may be needed to address prolonged skin carriage with MRSA 
and VRE as a strategy to reduce the risk for horizontal transmission as well as the potential to 
reduce subsequent infections among colonized patients.  
  
Previous studies in the prevention of catheter associated blood stream infections have indicated 
that there are a number of modifiable risk factors for catheter-associated bloodstream infection 
(15).  Most of these relate to proper sterile technique during the insertion and maintenance of 
central venous catheters (16). Proper site preparation with an effective skin disinfectant has 
been shown to be particularly important in reducing the incidence of subsequent catheter 
associated infections (17).  It is now recognized that chlorhexidine is superior to other agents in 
site preparation.  The use of chlorhexidine reduces residual skin organisms as well as inhibits 
their rebound growth and has been demonstrated to reduce CABSI in comparison to other skin 
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disinfectant products such as povidone-iodine.  CDC guidelines now recommend that the 
preferential use of chlorhexidine containing skin disinfectants be used for site preparation prior to 
insertion (17).   
 
The same properties that make chlorhexidine an effective agent in the prevention of CABSI have 
been utilized in selective settings to reduce the incidence of MRSA within the ICU.  
Chlorhexidene is an effective skin disinfectant that has been used successfully to eradicate 
MRSA skin colonization (18-20).  The reduction in skin colonization with MRSA (skin asepsis) is 
thought to lead to reduced risk for horizontal transmission of MRSA within the ICU environment.  
The use of chlorhexidine has been used successfully in the control of a number of MRSA 
outbreaks within the ICU setting and in the community (21,22).  
 
The role of chlorhexidine in reducing nosocomial infections highlights the importance of skin 
asepsis in the intensive care environment.  Although the selective use of chlorhexidine as it 
relates to catheter site preparation and in the selective treatment of MRSA colonized patients 
during outbreaks has received preliminary study, there is little study of the potential utility of 
more wide scale use of chlorhexidine in daily bathing routines within the ICU and hospital.  With 
daily bathing with chlorhexidine, there is the potential to reduce a number of nosocomial 
infections, including CABSI by reducing bacterial burdens on the skin.  Reductions in resident 
bacteria on the skin could lead to reduced horizontal transmission of multiresistant bacterial 
pathogens and better outcomes following central line insertions.  Daily bathing to produce a 
state of skin asepsis as such is an attractive theoretical means to reduce nosocomial infections 
because it represents a simple intervention that could be applied universally with relatively little 
effort.   
 
The goal of the currently proposed study is to determine if universal use of a chlorhexidine-
based bathing system for unit patients will decrease skin bacterial burden and lead to decreased 
transmission to ward mates resulting in reductions in the incidence of MRSA and VRE.  
Secondarily, we hypothesize that reduced skin colonization with opportunistic bacterial 
pathogens will result in a reduction in the rate of catheter-associated bloodstream infections and 
overall bacteremias in comparison to regular bathing procedures.  
 
5. Preliminary Studies 
Chlorhexidine has long been recognized as an effective skin disinfectant. In use for over 30 
years, chlorhexidine gluconate is used extensively as a surgical scrub, hand wash and skin 
cleanser.  Chlorhexidine is rapidly active and has persistent activity for 2-5 days after application 
leading to excellent skin asepsis after use.  Its use has been shown to lead to reduced infection 
after surgery when used as a perioperative skin preparation (23-25).  The use of chlorhexidine in 
skin site preparation for central line insertion has been shown to lead to a two-fold reduction in 
the incidence of bloodstream infections in comparison to povidone-iodine (26,27).  As such, 
chlorhexidine is recommended as one of the preferred agents for skin site preparation in the 
current CDC guidelines for catheter site care and use (17).  Wider use of chlorhexidine in the 
prevention of nosocomial infections recently has included its incorporation into catheter material 
to prevent catheter associated bloodstream infections (28). Chlorhexidine has also been used 
during a number of nosocomial outbreaks of MRSA infections to provide skin asepsis and 
reduce horizontal transmission of MRSA between patients (21,22). 
  
The use of chlorhexidine as a potential agent in the control of MRSA within the hospital 
environment has been an area of research at the McGuire VAMC during previous funding cycles 
for the CDC Prevention Epicenters.  Preliminary work has examined the role of chlorhexidine in 
 Page8 
reducing extra-nasal colonization with MRSA and the role of chlorhexidine at reducing MRSA 
transmission and infections within the intensive care unit.   
  
Beginning in July of 2003, the effectiveness of chlorhexidine in reducing extranasal colonization 
with MRSA following a hospital wide adoption of chlorhexidine bathing for all identified MRSA 
patients was examined at the McGuire VAMC in Richmond, Virginia.  Patients identified with 
MRSA were required to complete five days of daily bathing with chlorhexidine.  Serial cultures 
were taken and the extent of MRSA colonization followed over time.  Chlorhexidine was found to 
be a very effective agent in eradicating MRSA colonization. Table 1. presents the results of a 
cohort of patients that completed chlorhexidine bathing and had subsequent follow up cultures 
for up to three weeks.  
 
 
 
 
 
 
 
 
 
 
 
Based on these preliminary results, a focused intervention to determine if the more wide scale 
use of chlorhexidine bathing could reduce the incidence of MRSA in high-risk patients in the 
Intensive Care Unit was undertaken.  The study was a prospective evaluation of the selective 
use of mupirocin and chlorhexidine bathing for all patients identified with MRSA within a 
combined medical/coronary care unit.  During a nine month baseline period, the baseline 
prevalence and incidence of MRSA was determined through an active surveillance program that 
included nasal cultures for MRSA on admission to the unit and continued surveillance of 
identified MRSA patients with surveillance cultures taken three times a week.  No specific 
intervention other than the institution of contact precautions, barrier precautions and good hand 
hygiene for patients identified with MRSA was made during the baseline period.  During the 
planned nine-month intervention period all patients identified with MRSA were prescribed 
mupirocin for intranasal application for four days and received daily bathing with chlorhexidine 
for five days. The study took place between January 2003 and August 2004.  The results of the 
study are presented in Table 2.  
 
Table 2. Effectiveness of selective chlorhexidine bathing on MRSA incidence in the ICU 
(McGuire VAMC 1/03- 8/04) 
Study Period Admissions Admission 
Prevalence  
Prevalence per 1000 
ICU pt days (range) 
Incidence per 
1000 pt ICU days 
(range) 
Incidence per 1000 
days at risk (range) 
Baseline 845 11.00 %  29.33 (15.67-56.91) 6.62 (2.92-17.85) 8.45 (3.38-20.98) 
Table 1. Effect of chlorhexidine bathing on extranasal MRSA 
colonization 
Site of MRSA 
Colonization 
Patients with 
MRSA+ 
Initial 
Cultures 
Patients 
with 
Follow up 
cultures 
Patients with 
MRSA- 
follow up 
cultures 
Percent 
cleared 
Extranasal     
   Axilla 16 (17%) 10 8 80% 
   Perineum 35 (37.2%) 23 18 78.3% 
   Wound 5 (5.3%) 3 3 100% 
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Intervention 736 9.38% 21.01 (7.20-32.03) 3.35 (0-8.04) 4.05 (0-10.91) 
p=0.048 
 
The study has several important findings. The overall incidence of MRSA decreased 48% during 
the intervention period with 21 new MRSA cases detected during the baseline period and only 
11 new MRSA cases during the intervention period. (Table 2).  This resulted in a statistically 
significant difference in the incidence density [new cases of MRSA per 1000 patient days at risk] 
of 8.45 vs 4.05, p=0.048.  Second, the prevalence of MRSA at unit admission was slightly lower 
in the intervention period and this was directly attributable to chlorhexidine bathing and 
intranasal mupirocin that occurred both within the hospital and on former ICU patients (Figure 1).  
20/31 (65%) patients admitted to the unit with a previous history of MRSA had received 
chlorhexidine bathing prior to their admission and had negative surveillance cultures at the time 
of admission. Third, during the baseline period the majority of patients identified with MRSA 
were colonized for the duration of their ICU stay (55%). During the intervention period the 
duration of colonization with MRSA was substantially reduced. There were no reported problems 
attributed to the use of chlorhexidine bathing during the intervention.  MRSA isolates collected 
during the study underwent susceptibility testing to chlorhexidine.  Over 200 isolates were tested 
and there was no documented resistance to chlorhexidine using a breakpoint for MIC90 of 4 
μg/ml.  There was no evidence of acquired resistance to chlorhexidine or changes in MICs 
among serial isolates collected from patients. 
 
 
 
In this study, the possible benefits of the addition of chlorhexidine bathing in an ICU with active 
surveillance culturing in place were studied.  As such this study attempted to quantify the 
additional benefits of eradication of MRSA colonization in reducing MRSA incidence.  The use of 
chlorhexidine bathing and mupirocin were a means to produce skin asepsis and eradicate a 
large reservoir of MRSA within the unit.  The study examined the use of chlorhexidine in 
selected patients, as only patients identified with MRSA were the only patients who received 
chlorhexidine bathing.  The study found this to be a very successful strategy resulting in a 48% 
decrease in the incidence of MRSA beyond that seen with active surveillance culturing alone.  
These results were striking as the study was not initiated as a result on any outbreak or 
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Figure 1.  MRSA Prevalence and Incidence following the introduction of 
chlorhexidine bathing for MRSA patients 
(1/2003-8/2004)
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abnormally high rate of MRSA within the study unit, but as a planned prospective analysis 
prompted by a change in hospital policy.  
 
These encouraging results led to a second pilot study. The second pilot study differed from the 
first in that all study ICU patients received chlorhexidine (universal bathing), not just the subset 
of patients identified as MRSA carriers by surveillance cultures. This study was a prospective, 
before-after, interventional design taking place within a combined medical/coronary care unit and 
surgical ICU that took place from January 20005 to December 2005.  During a six-month 
baseline period, patients received bathing as usual.  Baseline rates of MRSA prevalence and 
incidence were determined by ongoing surveillance that included admission cultures for MRSA, 
weekly prevalence culturing and clinical cultures.  During the planned six-month intervention 
period, all patients admitted to the unit received daily bathing with chlorhexidine.  Bathing was in 
the form of a basin bed bath.  Approximately 4 ounces of 4% chlorhexidine solution was added 
to a basin filled with warm water. Patients were then bathed according to standard nursing 
protocols for bed baths with special care to avoid contact with mucous membranes and the 
eyes.  The results of the study were striking.  The overall incidence of MRSA decreased 45% in 
the two ICUs (Table 3).  The decrease in incidence was seen with similar rates of prevalence 
during both periods indicating a true decrease in incidence not related to burden of colonization 
within the units.  The overall incidence of nosocomial bacteremias decreased 25% from 8.8/1000 
patient days to 6.6/1000 patient days.   
 
Table 3. Effect of Daily Chlorhexidine Bathing among Patients Admitted to a combined 
CCU/MICU and SICU at the McGuire VAMC (1/05-12/05) 
 
Baseline Period 
(1/05-6/05) 
Intervention Period 
(7/05-12/05) 
MRSA cases (no of cases on admission) 55 39 
MRSA Prevalence (per 1000 patient days) 13.48 11.31 
Incident MRSA cases (n) 28 12 
Incidence Density (new cases per 1000 patient days) 8.27 4.57 
Incident Bacteremias (n) 36 23 
Bacteremia Incidence (new bacteremias per 1000 patient 
days) 8.8 6.6 
 
In 2005, three additional CDC Prevention Epicenters (Washington University, Memorial Sloan 
Kettering, and Johns Hopkins) also completed pilot studies of the effect of universal bathing with 
chlorhexidine in the ICU and its effect on the incidence of MRSA, VRE and nosocomial 
bacteremias. These three studies had a similar design to the study completed at McGuire.  All 
three studies were prospective, before-after, interventional designs.  Each had a six-month 
baseline period followed by a six-month intervention where all admitted patients to the study 
units received chlorhexidine bathing daily.  In addition to MRSA surveillance, surveillance for 
VRE was also completed in some units.  Again this surveillance included admission cultures for 
VRE as well as ongoing surveillance while patients were admitted to the study units. The intent 
of these pilot studies was to determine the possible impact of daily chlorhexidine bathing on the 
incidence of MRSA, VRE and nosocomial bacteremias.  These pilot studies were also designed 
to test the feasibility of a larger multi-center design and to independently confirm preliminary 
results seen at McGuire at other institutions.   
 
The results of preliminary data analysis are encouraging. Memorial Sloan Kettering has 
demonstrated a 67% decrease in the incidence of MRSA and a 50% reduction in the incidence 
of VRE following the introduction of universal bathing with chlorhexidine (Table 3).   
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At Johns Hopkins University, the pilot study was completed in two separate ICUs. The overall 
incidence of VRE decreased 41 % from 20.38 cases/1000 patient days to 12.06/1000 patient 
days. The overall incidence of incident bacteremias/fungemias decreased 44% from 2.74/1000 
patient days to 1.53/1000 patient days (Table 4).  More importantly, the reduction in bloodstream 
infections was noted among all organism types. Reductions were seen in the number of 
fungemias and bacteremias, including enterococci, gram positives, and gram negative 
organisms (Figure 2). 
 
 
 
In summary, several pilot studies completed within the CDC Prevention Epicenters between 
2002 and 2006 indicate that universal bathing with chlorhexidine may be a very effective 
modality to reduce the incidence of MRSA, VRE and nosocomial bacteremias.   
 
As encouraging as the data from the second pilot study may be, there are several 
methodological limitations.  First, the study was not designed as a multicenter randomized 
control trial.  Each participating center conducted the pilot study as a stand-alone project and 
while the same definitions and similar methodologies were used, they were not identical.  As an 
example, all of the studies have studied the use of chlorhexidine used in basin baths. Typically a 
four percent solution of chorhexidine was added to a basin filled with water and patients were 
bathed by nursing personnel in bed. This method of basin baths is often inefficient; results in 
varied concentrations of chlorhexidine and cannot be completed on all patients, particularly 
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Figure 2.  Reduction in Bacteremias and Fungemias Following the Use of 
Daily Chlorhexidine Bathing- Johns Hopkins University
Control Period (January-
June 2005)
Intervention Period (July-
December 2005)
Table 3. Effect of Daily Chlorhexidine Bathing among ICU Patients  
Memorial Sloan Kettering (1/05-12/05) 
 
Baseline 
(1/05-6/05) 
Intervention  
(7/05-12/05) 
MRSA Admission Prevalence 6.08%    7.10% 
MRSA Incidence (n) 15    4 
MRSA Incidence (cases per 100 patient days) 5.73    1.59 (p=0.024) 
VRE Admission Prevalence  17.63    14.52 
VRE Incidence (n)  33    17 
VRE Incidence (cases per 1000 patient days) 14.73    7.42 (p=0.020) 
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those with serious medical problems.  As such compliance with bathing reported during pilot 
studies ranged from 70-95%.  Secondly, the number of study patients from each institution is 
small, and even if the results from individual institutions can be combined, there may be 
insufficient numbers (sample size and power) to detect a statistically significant reduction in 
BSIs.  These methodologic issues suggest the need for a larger multicenter trial and ideally, the 
use of a product that would allow for standardized concentrations of chlorhexidine.   
 
In 2002, SAGE Products, Inc., developed a new product to be used for bathing patients. Sage, 
inc. is a large supplier of healthcare products to hospitals including the Comfort Bath® washcloth 
system (see Appendix).  Many hospital systems use the Comfort Bath product that allows for 
simple bathing of patients without the need for soap, water or basins.  The Comfort Bath 
washcloth system contains eight pre-moistened washcloths that are used to wipe and cleanse 
each are of the body.  They are disposed of after use. The procedure requires no soap and 
water. In 2002 Sage developed a new washcloth impregnated with 2% chlorhexidine.  These 
washcloths reduce the number of microorganisms on the skin and deliver residual antimicrobial 
activity for a prolonged period of time. In the first pilot trial of the effectiveness of the new 
chlorhexidine impregnated washcloth, Vernon et al examined 1787 patients admitted to a 
medical intensive care unit from October 2002 to December 2003 (29).  They were able to 
document a reduction in the skin colonization with VRE for those cleansed with the new product 
as well as a 65% reduction in the incidence of VRE (26 per 1000 patient days to 9 per 1000 
patient days). Additionally they noted reductions in the level of environmental contamination and 
the level of contamination of healthcare worker’s hands with VRE.   This new product was well 
tolerated and resulted in higher compliance with daily bathing and also delivered standard 
concentrations of chlorhexidine. These data in combination with those previously generated in 
the CDC prevention Epicenters would indicate that this product would be an ideal candidate for 
further study of the effects of chlorhexidine bathing in a larger multicenter trial. 
 
6. Research Design and Methods 
 
6.1 Hypothesis:  
 
A change in the regular bathing procedures to utilize products containing chlorhexidine will 
result in a reduction in the number of colonizing bacteria, including MRSA and VRE, on the 
skin of patients.  Reduced colonization of the skin (skin asepsis) will lower the incidence of 
nosocomial transmission of bacteria in the ward and decrease incident cases of new 
bacteremias caused by these bacteria.   
 
6.2 Design:   
Prospective, cluster randomized, stratified, crossover trial of units. Units will serve as the as 
the units of randomization and as their own control.  Units will be stratified by the presence 
of active surveillance culturing for MRSA and/or VRE at the time of study entry.  
 
6.3 Study Setting:   
The study will take place in two or more units per participating hospital.  Approximately 14 
units will be enrolled.  Enrolled units will be predominantly intensive care units (ICUs) 
although additional units where active surveillance for MRSA and or VRE takes place will 
also be enrolled to include a Bone Marrow Transplant unit, a Burn unit and a Hematology 
Oncology ward. Study personnel will track blood culture data, patient-days, and MRSA and 
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VRE specific data per protocol.  Units must have pre-existing active surveillance for MRSA 
and/or VRE in place at the time units undergo randomization in order to participate.   
6.4 Participating Hospitals: 
 
McGuire Veteran Affairs Medical Center (Coordinating Center) 
Richmond, Virginia 
 Principal Investigator: Michael Climo 
 Co-Investigators: Edward Wong, Jane Cecil 
Johns Hopkins University 
Baltimore, Maryland 
 Co-investigator: Trish Perl 
Memorial Sloan Kettering 
New York, New York 
Co-investigator: Kent Sepkowitz 
Brigham and Women’s Hospital 
Boston, Massachusetts 
Co-investigator: Debbie Yokoe 
University of Iowa 
Iowa City, Iowa 
Co-investigator: Loreen Herwaldt 
Northwestern University 
Chicago, Illinois 
Co-investigator: Maureen Bolon 
Washington University 
St. Louis, Missouri 
Co-investigator: Dave Warren 
 
6.5 Intervention:  
Selected units will be randomized to start with either Comfort Bath wash clothes or new 
chlorhexidine containing wash clothes.  The unit of randomization will be a single unit.  The 
units will utilize the randomized bathing procedure (Comfort Bath washcloths or washclothes 
impregnated with 2 % chlorhexidene) for all patients admitted to the participating unit for a six 
month period of time and then switch to the alternative product for an additional six month 
period (figure 3).  The periods that utilize the regular Comfort Bath wash clothes (control 
periods) will be compared to the periods in which the washcloths impregnated with 
chlorhexidine (Intervention period) are used for each ward.  Patients will be bathed daily with 
data collection on the compliance with daily bathing.  Many skin care moisturizers that 
contain anionic emulsifiers may adversely affect the residual antibacterial effect of 
chlorhexidine and should be avoided during routine care during periods in which 
chlorhexidine is in use.  Skin care products that are known to be compatible with 
chlorhexidine include: Aquaphor® Original Formula Ointment, Lubriderm® Dry Skin Care 
Lotion, Eucerin® Original Lotion, Vaseline® 100% Pure Petroleum Jelly, PROVON® 
Moisturizing Lotion.  Participating study units will be asked to utilize one of these products for 
skin care during the proposed study.  Data collection during the study will include all positive 
blood cultures, patient days for study units as well as additional data on MRSA and/or VRE 
colonization and infection among admitted patients.   
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Figure 3.  Randomization Sceme  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.6 Outcome measures:  
 
1.  Overall rate of nosocomial BSI with significant bacterial pathogens during the control 
period in comparison to the rate during the use of chlorhexidine bathing. 
 
A. Specific rates will include: 
 
1) Number of MRSA bacteremias per 1000 patient days 
 
2) Number of VRE bacteremias per 1000 patient days 
 
3) Total number of bacteremias for all significant bacterial and fungal 
pathogens per 1000 patient days 
 
4) Number of bacteremias or fungemias for individual pathogens per 1000 
patient days. 
 
B. Bacteremias will include only first significant bacteremia/fungemia for patients 
during each ICU or ward admission and will not include duplicate bacteremias 
during a single ICU or ward admission.  Significant bacteremias will also only 
include bacteremias with organisms not considered to be skin contaminants (see 
organism key Appendix B for definition) 
 
C. Due to the large number of patients involved in this study and its prolonged 
nature we have elected not to collect line days for each unit.   Active surveillance 
of this nature is time consuming and unlikely to add additional information to the 
study as we are studying an intervention intended to reduce the overall rate of 
BSI within the study units.  As such the denominator for all calculations will be 
total patient days.  This is a reasonable surrogate measure of line days in the 
intensive care unit as up to 87% of all ICU associated BSI are catheter 
associated ().  Bloodstream infections will be characterized as catheter 
associated or not catheter associated. 
 
2. Overall rate of incident cases of MRSA/VRE colonization and infection (incidence 
density) in the baseline period in comparison to the rate during the use of 
chlorhexidine bathing.  Specific calculated rates will include: 
Presence of Active Surveillance
Randomization 
First Six Months  Second Six Months 
14 units
MRSA Only
VRE only 
MRSA and VRE 
Control
Control
Control
Control
Control
Control
Intervention
Intervention
Intervention
Intervention
Intervention
Intervention
Anticipated 
Number of Units 
4 
1 
1 
2 
4 
2 
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A. Number of new MRSA/VRE positive patients per total number of patients.  Monthly 
range and variance.   
 
B. Number of new MRSA/VRE positive patients per 1,000 patient days.  Monthly 
range and variance. 
 
C. Number of new MRSA/VRE positive patients per 1,000 eligible patient days.  
Monthly range and variance.  Eligible patient days are those days susceptible 
patients were at risk for acquisition of MRSA or VRE [Total patient days – total 
patient days for patients identified with MRSA or VRE] This denominator reflects 
the true incidence of colonization or infection.  
 
6.7 Data collection: 
  
6.71 Patient Specific Information:   
 
Each patient admitted to the study unit during the study periods will be recorded and 
assigned a specific study number. The dates of admission, dates of discharge, study 
unit will be recorded and used to calculate length of stay and to determine the 
incidence of nosocomial infections based on microbiological data.  Data entry will be 
entered into a password protected Access database. The Access database was 
developed during previous pilot work within the CDC prevention Epicenters (2003-
2006) and has been used extensively by four centers (Johns Hopkins, McGuire, 
Memorial Sloan Kettering and Washington University) during their single institution 
evaluation of the effectiveness of chlorhexidine bathing. (see Appendix A).  As with 
previous work completed within the CDC Epicenters, patient identifiers (in this case 
patient names and medical record number) will be removed from the database prior to 
submission to the coordinating center (McGuire). This data and research will not be 
used or disclosed to any persons or entity outside of the study institutions.  All data 
collection files will be password protected and stored on computers belonging to study 
investigators.  Personal health information will be maintained with the database during 
the collection of unit census data, microbiology data, and medical record review.  All 
patients will be assigned a study identification number that is unique to each 
institution.  Each participating institution will maintain a password protected code key 
file at their institution that will link study identifiers to patient identifiers.  This code key 
will be accessible only to study investigators and study staff.  Any hard copies of 
datasets will be stored in a locked filing cabinet.  After all data are collected, analyzed, 
and published, linkage between patients and their unique identifier will be destroyed, 
with the exception of data collected through Infection Control Departments as part of 
hospital operations.  Identified datasets related to infection control activities will be 
maintained at the primary institution according to hospital operations policy.   
   
6.72 MRSA Screening:  
 
Microbiological data on all MRSA surveillance performed within the study unit will be 
recorded for those units who have active surveillance in place.  Active surveillance will 
be defined as cultures for MRSA within 48 hours of admission and at least once 
weekly while admitted to the unit or at time of discharge.  Data entry will be entered 
into a password protected Access database. An incident case will be defined as any 
patient with a positive active surveillance or clinical culture > 48 hours after ICU 
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admission in patients with either previous negative surveillance and clinical cultures or 
no previous history of MRSA.  Prevalent cases will be defined as any patient with 
positive active surveillance cultures or clinical cultures collected within 48 hours of 
admission. Weekly reports on compliance with admission surveillance cultures for all 
admitted patients will be monitored and reported during weekly teleconferences.   
 
6.73 VRE Screening:  
 
Microbiological data on all VRE surveillance performed within the study unit will be 
recorded for those units who have active surveillance in place.  Active surveillance will 
be defined as cultures for VRE within 48 hours of admission and at least once weekly 
while admitted to the unit or at time of discharge.  Data entry will be entered into a 
password protected Access database.  Incident and prevalent cases will follow the 
same definitions as above for MRSA patients.  Weekly reports on compliance with 
admission surveillance cultures for all admitted patients will be monitored and reported 
during weekly teleconferences.   
 
6.74 Clinical Culture Data:   
 
Microbiological data on all clinical cultures positive for MRSA or VRE will be entered 
into the Access database.  These data will be compiled with surveillance data in order 
to determine prevalence and incidence rates for MRSA and VRE.  
 
6.75 Blood culture data:  
 
Data on all positive blood cultures will be collected for significant bacterial/fungal 
pathogens if they occurred >48 hours after unit admission and within 48 hours of 
discharge from the study unit.  This will include all organisms with the exception of 
common skin contaminants and all coagulase negative staphylococci (see organism 
key Appendix B).  Data collected will be entered into a password protected Access 
database.  Incident bacteremias (or fungemias) will include only the first significant 
bacteremia with a significant bacterial or fungal organism during the unit admission 
and will not include duplicate organisms or subsequent infections, as the primary aim 
of the study is to prevent incident cases.  
 
6.76 Mupirocin Use: 
 
Each Study patient will have information about the concurrent use of mupirocin use 
during the admission recorded.  This information is being collected to determine if 
concurrent mupirocin use affects the clearance of MRSA from the study population.  
Use of any mupirocin during the admission will be recorded in the Access Database. 
 
6.77 Compliance Monitoring:  
 
Confirmation of compliance with daily bathing will be collected by individual centers on 
a weekly basis during both the baseline and intervention periods.  Compliance 
monitoring will consist of monitoring the use of Comfort Bath washcloth packages and 
new washcloth packages impregnated with 2% chlorhexidine during the week and 
ensuring that adequate supplies exist. The total quantity of washcloth packages used 
during the week will be entered into a compliance monitoring worksheet. For the 
purposes of this study, use of one washcloth package will be considered receipt of 
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one patient bath.  Oversight of the trial will not include direct observation of bathing.  
Previous work completed during pilot studies has indicated that the overwhelming 
majority of bathing occurs during the evening and late night shifts making it nearly 
impossible for research personnel to perform direct observation.  Since the Comfort 
Bath washcloth package is designed to complete one patient bath it is reasonable to 
assume that use of one product will represent receipt of one bath. At the time of data 
analysis, the use of Comfort Bath washcloth packages and washcloth packages 
impregnated with 2% chlorhexidine will be compared to the number of patients in the 
study unit to determine the approximate compliance with bathing. 
 
6.78 Data Collection Forms 
 
All data will be entered at the participating site into an Access Database (see 
Appendix A)  Data will include basic demographic information on study patients as 
well as all culture information to include MRSA screening, VRE screening and blood 
culture data.  The database will be password protected at the site.  Definitions for all 
database fields are contained with in Appendix C.  Prior to submission to the 
coordinating center (McGuire), patient identifiers (name and medical record number) 
will be removed from the database. 
 
6.8 Trial Oversight:  
 
All principal investigators will serve on the steering committee for oversight of the trial.  All 
investigators have participated previously in weekly teleconferences to develop, implement, 
and analyze multicenter projects during previous CDC Prevention Epicenter Funding 
(1999-2006). Oversight of this trial will follow a similar design with weekly teleconferences 
of the steering committee. At that time there will be weekly discussions of the progress 
report, reporting of compliance with active surveillance, reporting of compliance with 
bathing, and any adverse reactions or other weekly problems.  
 
6.9 Statistical Analysis:  
 
The effect of daily bathing with chlorhexidine impregnated washcloths on incidence density 
of BSI, MRSA, and VRE incidence will be modeled by means of Generalized Estimating 
Equations (GEEs) under the Poisson distribution family.  Since each unit is observed twice 
under the study’s crossover design (once under the experimental and once under the 
control condition) and the targeted outcome is in the form of counts (here new cases or 
infections related to patient days of exposure), the GEE methodology is needed to model 
the count outcomes while accounting for the natural clustering effects induced by repeated 
observation of units.   
 
Our study design requires three separate analyses based upon the type of surveillance 
(MRSA only, VRE only, or both) employed by the units.  The analysis of BSI rates will use 
data from all units and will incorporate a three level fixed effect designating surveillance 
type.  The analyses of MRSA and VRE rates, respectively, will be based on only those 
units engaging in the corresponding type of surveillance.  In the latter analyses, a two level 
fixed effect for surveillance type will be incorporated (MRSA only versus both - or VRE only 
versus both).  
 
The fundamental model in these analyses will specify treatment, order of presentation, and 
type of surveillance fixed main effects.   Offsets in each model will be unit specific total 
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patient days during the exposure periods.  Even though the study design targets minimizing 
order and type of surveillance effects and neither are expected to be present in any 
magnitude, their possible effects will incorporated for control purposes.  If either proves to 
be significant, their interactive effects with treatment will also be examined.  Such 
interactive effects are likewise not expected to be present. 
 
All significance tests in these analyses will be conducted given two-tailed alpha of .05.  In 
addition, 95% confidence intervals estimating treatment and control rates as well as their 
ratio will be constructed.  It should be noted that in this study, there can be no missing data 
and consequently no missing data issues.  Analyses are planned to be conducted using the 
SAS System for Windows Genmod procedure (Version 9.1.3 or later). 
 
6.10 Power considerations: 
 
For power estimation, we have conservatively assumed that 12 units (4 units with both 
MRSA and VRE surveillance and 4 each using only one of the surveillance types) will be 
randomized under the study design.  Based upon our prior experience with admission rate, 
length of stay and observed infection rates in such units, we anticipate an average 
incidence density rate (new cases of MRSA per 1000 patient days) of 8 per 1000 patient 
days for MRSA, an average incidence density of 15 per 1000 days for VRE, and an 
average incidence of 8 1000 patient days for new nosocomial BSIs a during each unit’s 
control exposure.   
 
The following table shows power estimates corresponding to the test of treatment effect 
assuming six-month exposures.  Power estimations are based on 1000 iterations of data 
randomly drawn from Poison distributions and analyzed via GEE for the treatment effect 
assessed.  Each cell in the table represents the power estimate for a specified combination 
of control rate and reduction rate due to treatment: 
 
Table of power estimates: 
 
Control Rate/1000 
Patient Days: 
BSI 
7 
BSI 
8 
BSI 
9 
MRSA 
7 
MRSA 
8 
MRSA 
9 
VRE 
14 
VRE 
15 
VRE 
16 
Reduction:          
30% 98% 99% 99% 94% 98% 98% 99% 99% 99% 
25% 94% 98% 99% 86% 88% 92% 98% 98% 99% 
 
 
Based upon prior research, we expect rate reductions to exceed 30%.  As the table shows, 
the study should have at least 95% power to detect 30% or greater rate reductions and 
85% or greater power to detect reductions as small as 25% in all three measured rate 
analyses.  Hence, the study will be more than adequately powered.  In fact, based on the 
number of enrolled units we estimate that we would be powered to detect a 30% reduction 
in MRSA, VRE and nosocomial bacteremias with incidence rates as low as 3.5/100 patient 
days, 4.5/100 patient days and 3.5/1000 patient days respectively during the control period.  
 
6.11 Economic Analysis 
  
In addition to understanding the effectiveness of the chlorhexidine impregnated washcloths 
it is important to estimate the cost-effectiveness of the interventions. We hypothesize that 
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regular bathing utilizing products containing chlorhexidine will result in a reduction in the 
number of colonizing bacteria including MRSA and VRE on the skin of patients.  The 
reduced colonization of the skin will lower the incidence of nosocomial transmission of 
bacteria in the ward and decrease incident cases of new bacteremias caused by these 
bacteria.  Thus, the use of chlorhexidine impregnated washcloths may reduce the incidence 
of high cost MRSA and VRE infections in patients in intensive care units. Therefore it is 
important to examine the cost-effectiveness of the use of chlorhexidine impregnated 
washcloths.   
  
There are three potential scenarios that could exist with the use of the chlorhexidine 
impregnated washcloths, of which one is unlikely based on pilot data. First, the washcloths 
could reduce the rate of nosocomial infections enough to offset the increased costs 
associated with the use of the chlorhexidine impregnated washcloths in which case the new 
intervention would be considered cost-savings. The second scenario is that the washcloths 
will decrease the rate of nosocomial infections but increase the total costs of care where it 
is then important to determine the cost-effectiveness (value) of the washcloths. The final 
scenario, which again is less likely based on the pilot data, would be where the washcloths 
are less effective than current bathing practices and more costly where the chlorhexidine 
impregnated washcloths would be dominated by the current bathing practices. A final 
scenario that is a possibility in cost-effectiveness analyses is where the chlorhexidine 
impregnated washcloths would be less effective and be associated with lower costs. This 
scenario occurs infrequently when the new technology, chlorhexidine impregnated 
washcloths in this case, cost more than the previous standard of care. 
 
To evaluate the cost-effectiveness of the chlorhexidine impregnated washcloths we will 
undertake two specific tasks: 
 
1. Compare the costs in the intervention and control arms of the trial; and 
 
2. Evaluate the cost-effectiveness of chlorhexidine impregnated washcloths compared 
to standard bathing practices by adapting a previously published model. 
 
For the first task we will compare the hospitalization costs between the two arms of the 
study. For each of the study arms, we will determine the length of stay for each 
hospitalization, the rate of colonization and the rate of nosocomial infections.  We will 
estimate the total cost of hospitalization for each individual included in the study. Because it 
is impractical to obtain billing data for each of the patients included in all of the institutions 
for the study we will estimate the hospitalization costs for individuals included in the trial. 
Using estimates reported in the literature or national averages may make the results more 
generalizable than relying on billing data from the eight institutions involved in the study. 
For the control arm, hospitalization costs will be a function of the length of stay, the average 
per diem cost for a hospitalization and the per diem costs associated with a nosocomial 
infection. 
 
 Total costscontrol = (LOSno infection * per diem costno infection) + (LOSinfection * per diem 
costinfection) 
 
For the treatment arm, the hospitalization costs will be similar to that of the controls with the 
incremental costs associated with chlorhexidine impregnated washcloths included in the 
equation. 
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Total coststreatment = (LOSno infection * per diem costno infection) + (LOSinfection * per diem 
costinfection) + ((Cost chlorhexidine washcloths – cost Comfort Bath washcloths) * number of 
washcloths)) 
 
The per diem costs for infections will be estimated using the same procedure we have used 
in previous work (30).  For example, for VRE infections the per diem cost will be estimated 
by combining total VRE cost estimates from Stosor and colleagues (31) ($83,897 – 
$56,707 = $27,190) with the length of stay data for VRE infections from Monteclavo et al. 
(32) (26.3 – 12.6 = 13.7 days) and adjusting to current year dollars ($27190/13.7 = $1984 
per day [1995 $] * Medical care component of CPI = cost in current year dollars). Similar 
methods will be used to estimate MRSA and other nosocomial infection costs based on 
previously published cost estimates (5). 
 
The difference in total hospital costs will be compared between the groups.  Because cost 
data typically does not conform to the necessary assumptions of normality when comparing 
means, the costs will be compared using non-parametric bootstrap techniques (33,34). The 
bootstrap methods, as described by Barber and Thompson (33) and Desgangné (34) allow 
for the estimation of differences in costs and the calculation of confidence intervals for the 
difference. The non-parametric approach makes no underlying assumptions about the 
distribution of the data and yet compares the arithmetic means and differences in arithmetic 
means. 
 
The bootstrap comparison will be done by sampling, with replacement, the costs from each 
of the groups until the original sample size in each arm is reached and calculating an 
average cost for each of these replicates. The difference in average costs will then be 
calculated between groups. This process will be repeated 1000 times to compare the 
average difference in hospitalization costs between control and intervention patients and 
the confidence interval surrounding the difference. 
 
The second task will involve comparing the cost-effectiveness of the intervention with the 
control in terms of cost per life year saved. To complete this task, we will modify a 
previously published model in which we evaluated the cost-effectiveness of screening 
programs for VRE (30).  The figures below show the structure of the model that will be 
easily adaptable to the comparison of the interventions rather than a screening program. To 
adapt the model, the two primary branches of the tree will be similar to the structure in the 
“No screen” branch in Figure 4 below. Both the intervention and control arms will have the 
same structure and the probabilities associated with the branches will come directly from 
the clinical trial. That is, the rate of colonization and infection for each arm of the decision 
tree will be based on the overall results from the clinical trial. The costs associated with 
each arm of the decision tree will be based on the hospitalization costs that were estimated 
above.  
 
In addition to the decision-tree portion of the model there is also a Markov component of 
the model that accounts for the benefit of reducing colonization and infections within a unit 
(figure 5).  This benefit is seen by reduced risk of nosocomial infections to patients in the 
unit that are not currently colonized.  The Markov process will be adapted to not only 
include the rate of transmission of VRE but of other nosocomial infections. 
 
The incremental cost-effectiveness ratio (ICER) will be calculated comparing the 
incremental costs and benefits associated with the intervention compared to the control. 
The formula for the ICER is: 
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 ICER = (Costintervention – Costcontrol) / (Outcomeintervention – Outcomecontrol)  
 
The outcome that will be used in the cost-effectiveness analysis is life years. The base 
case will be the mortality rate observed in each arm of the study to determine the life years 
saved attributable to the intervention. However, because we may not have sufficient power 
to compare mortality in the study, we will also use the estimated risk of mortality associated 
with nosocomial infections in a sensitivity analysis.  All analyses will be conducted from the 
perspective of the hospital.  Additionally, we will conduct a fully probabilistic analysis on the 
decision model.  Patients will move through the decision model based on the probability 
values at each of the nodes on the model.  We compared the surveillance strategies with a 
probabilistic analysis of the analytic decision model, which involves assigning a distribution 
to the probability values at certain nodes of the model rather than a single value (35-37).  
The probability for the value is then chosen randomly from this distribution through Monte 
Carlo simulation.  Using a probabilistic decision model incorporates uncertainty associated 
with the parameter estimates rather than relying on a single value to represent the 
estimate. 
 
Results will be reported as cost per life year saved associated with the intervention 
compared to the controls. We will compute 95% confidence intervals for the incremental 
cost-effectiveness ratio, plot the results on cost-effectiveness planes and produce cost-
effectiveness acceptability curves. In addition to the fully probabilistic analysis we will also 
conduct several sensitivity analyses. We will conduct one-way analyses on all variables 
included in the model. From the one-way analyses we will produce a funnel plot of the most 
influential parameters. We will also conduct two-way and multi-way sensitivity analyses on 
parameters that are thought to be correlated and co-vary with each other. 
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Figure 4. Decision tree 
 
Model – Markov Process
No VRE
VRE Infection
Discharged Died
 
Figure 5. Markov process of the model 
 
6.12 Chlorhexidine Resistance 
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Resistance to chlorhexidine is rare among both staphylococci and enterococci with 
reported MIC’s to chlorhexidine for staphylococci of 0.2 –3 μg/ml [0.00002-0.0003%] and 
for enterococci of 1-6 μg/ml [0.0004-0.0006%] (38-41).  Previous studies have also 
indicated that following serial passage of both staphylococci and enteroccci in the presence 
of chlorhexidine there are only minimal changes in MIC values and no evidence of reported 
high-level resistance (38). Plasmid mediated resistance to antiseptics and disinfectants 
among staphylococci is well known. Most prevalent is the presence of the qacAB and 
qacCD  gene families that encode proton dependent export proteins that confer resistance 
to a wide variety of disinfectants.  Most prevalent among staphylococci is the qacA 
determinant found on the pSK1 family of conjugative plasmids that also typically encode 
resistance to a number of antimicrobials including ß-lactamase (42).   The presence of 
qacA results in substantial increases in MIC’s to quaternary ammonium compounds 
(QAC’s) but only a 2.5 fold increase in MIC’s to chlorhexidine (0.8 μg/ml to 2 μg/ml), 
corresponding to concentrations well below those seen in commercial preparations of 
chlorhexidine (38).  Plasmid mediated resistance to chlorhexidine has not been described 
among enteroocci.  High level resistance to chlorhexidine among gram-negative bacterial 
organisms particularly Pseudomonas and Serratia has been reported (43-45).  However 
many gram-negative organisms, fungal, and mycobacterial organisms remain susceptible 
to chlorhexidine. 
 
With such widespread use of chlorhexidine that is anticipated during this proposed trial, we 
will test isolates for chlorhexidine resistance.  Each participating center will ship isolates of 
staphylococci and enterococci collected within the study units to the coordinating center 
(McGuire VAMC).  We will adopt a sampling strategy for testing given the large number of 
units and patients involved in the study.  Each participating center will collect the first ten 
bacterial isolates (five MRSA and five VRE) from patients treated in the study during the 
calendar month and each month thereafter.  Culture specimens will be labeled with a 
unique Study number identifier corresponding to the identifier in the database form and as 
such will contain no unique identifiers contained within the 18 HIPAA identifiers.  Over the 
twelve month duration of the study, we will collect 1,920 isolates of MRSA and VRE for 
testing.  All isolates will be tested for susceptibility to chlorhexidine.  MIC’s for chlorhexidine 
will be determined by an agar dilution method on Mueller-Hinton agar containing 
chlorhexidine diacetate (Sigma-Aldrich Inc., St. Louis, MO) in concentrations ranging from 1 
to 16 μg/ml (corresponding to 0.0001% to 0.0016%). Although no standard definition exists 
for resistance to chlorhexidine, previous studies have indicated that most isolates of MRSA 
and VRE have MIC’s <8 μg/ml (0.0008%).  For the purposes of this study, isolates with 
MIC>16 μg/ml will be considered resistant.  Susceptibility to chlorhexidine will be compared 
between periods where chlorhexidine impregnated washcloths were in use to determine if 
acquired resistance to chlorhexidine developed following its wide-scale introduction. 
Although the primary goal of this testing is to determine any level of resistance to 
chlorhexidine among clinical isolates of MRSA and VRE, this effort will represent the 
largest survey of clinical isolates of MRSA and VRE for susceptibility to chlorhexidine 
completed to date.   
 
7. Human Subjects Research Considerations 
 
7.1 Human Subjects Involvement and Characteristics  
This is a cluster-randomized trial with an intervention that is based at the unit level. The 
“intervention” is examining two accepted bathing methods and the possible differences in 
the development of nosocomial infections based on the use of these products.  Because 
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both SAGE washcloth products are FDA approved products, we will be seeking a waiver of 
documentation of informed consent.  All patients admitted to the units enrolled in this study 
will undergo bathing with two different bathing products (Comfort Bath Wash clothes or 
Wash clothes impregnated with 2% chlorhexidine) according to a randomization schedule.  
Both bathing products are FDA approved. The 2% chlorhexidine gluconate cloth is FDA 
approved as a patient perioperative skin preparation and for use to reduce bacteria that can 
potentially cause skin infection.  It is for this latter use that this study will use the product.  
Comfort Bath Wash clothes are used extensively as a basin-less form of patient bathing.  
The study will determine potential differences between the use of the two products and the 
incidence of MRSA, VRE and nosocomial bacteremias.  The proposed units are 
predominantly Intensive Care Units, Bone Marrow Transplant units and Hematology-
Oncology wards.  This indicates that the targeted patient population will be varied and will 
include a number of critically ill patients.  Intensive care units that will participate will include 
surgical intensive care units, medical intensive care units and cardiology intensive care 
units.  Patients in these units typically have a variety of medical conditions including post-
surgical problems, myocardial infarctions, coronary artery disease and a number of 
infectious and complex medical care requiring intensive unit care.  The expected age range 
of human subjects will be from 18-90 years of age as we will only be including units that 
serve adult populations. Both men and women will be included in the research. The 
proposed research will take place in six additional hospitals that include: Johns Hopkins 
University, Brigham and Women’s Hospital, Northwestern University, Washington 
University, Iowa University and Memorial Sloan Kettering.  
 
7.2 Sources of Materials  
Each patient admitted to study units during the study periods will be recorded and assigned 
a specific study number. The dates of admission, dates of discharge, study unit will be 
recorded and used to calculate length of stay and to determine the incidence of nosocomial 
infections based on microbiological data.  Additional data that will be collected include birth 
decade, gender, and all microbiologic data for positive surveillance or clinical cultures for 
MRSA or VRE. All positive blood cultures will also be recorded. Data entry will be entered 
into a password protected Access database. The Access database was developed during 
previous pilot work within the CDC prevention Epicenters (2003-2006) and has been used 
extensively by four centers (Johns Hopkins, McGuire, Memorial Sloan Kettering and 
Washington University) during their single institution evaluation of the effectiveness of 
chlorhexidine bathing. (see Appendix A).  As with previous work completed within the CDC 
Epicenters, patient identifiers (in this case patient names and medical record number) will 
be removed from the database prior to submission to the coordinating center (McGuire). 
This data and research will not be used or disclosed to any persons or entity outside of the 
study institutions.  All data collection files will be password protected and stored on 
computers belonging to study investigators.  Personal health information will be maintained 
with the database during the collection of unit census data, microbiology data, and medical 
record review.  All patients will be assigned a study identification number that is unique to 
each institution.  Each participating institution will maintain a password protected code key 
file at their institution that will link study identifiers to patient identifiers.  This code key will 
be accessible only to study investigators and study staff.  Any hard copies of datasets will 
be stored in a locked filing cabinet.  After all data are collected, analyzed, and published, 
linkage between patients and their unique identifier will be destroyed, with the exception of 
data collected through Infection Control Departments as part of hospital operations.  
Identified datasets related to infection control activities will be maintained at the primary 
institution according to hospital operations policy.   
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7.3 Waiver of Documentation of Written Informed Consent 
This study will involve all adult patients admitted to the proposed study units. As such there 
is no recruitment strategy. It is intended to encompass all patients within the participating 
units. This study will be seeking waiver of documentation of written informed consent in 
accordance with 21 CFR 56.109(c): 
“An IRB shall require documentation of informed consent in accordance with Sec. 50.27 of 
this chapter, except as follows: (1) The IRB may, for some or all subjects, waive the 
requirement that the subject, or the subject's legally authorized representative, sign a 
written consent form if it finds that the research presents no more than minimal risk of harm 
to subjects and involves no procedures for which written consent is normally required 
outside the research context; or (2) The IRB may, for some or all subjects, find that the 
requirements in Sec. 50.24 of this chapter for an exception from informed consent for 
emergency research are met.”  
1. The intended research presents no more than minimal risk to the patients.  The intent is 
to study the potential differences between two accepted bathing products for patients and 
to determine if there is the potential to reduce nosocomial infections.  Both products are 
FDA approved products and as such pose minimal risk to those patients involved.  Bathing 
with chlorhexidine is an accepted procedure within the hospital and is often applied to 
selected patient populations within the hospital including pre-operative patients.    
 
2. The activities within the proposal do not normally require informed consent. Bathing is an 
accepted practice within the hospital and does not require written informed consent.  
Surveillance cultures are normally done in the course of many hospital surveillance 
activities and the standard of care is to require only verbal permission prior to collection.   
 
In accordance with 45 CFR 56.109(d), subjects in the trial will be given a written statement 
about the nature of the study. 
“(d) In cases where the documentation requirement is waived under paragraph (c)(1) of this 
section, the IRB may require the investigator to provide subjects with a written statement 
regarding the research. “ 
An example of the patient information sheet is included in Appendix I.  
7.4 Waiver of HIPAA Authorization 
 
This clinical research study will be seeking waiver of written HIPAA authorization based on 
the following: 
 
1. Use or disclosure of protected health information involves no more than minimal risk to 
the privacy of individuals. We will keep all data in a secure Access database that is 
password protected and accessible only to dedicated research personnel. Data entry for 
individual patients will be coded and not include patient’s full name or complete social 
security number.  All patients will be assigned a study identification number that is unique 
to each institution.  As with previous work completed within the CDC Epicenters, patient 
identifiers (in this case patient names and medical record number) will be removed from the 
database prior to submission to the coordinating center (McGuire).  Following this de-
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identification, the only protected health information contained within the database that will 
be forwarded to the coordinating center (McGuire) are the dates of admission and 
discharge dates from the study units.  None of the other protected health Information 
identifiers are contained within the database. Personal health information will be maintained 
with the database during the collection of unit census data, microbiology data, and medical 
record review.  Each participating institution will maintain a password protected code key 
file at their institution that will link study identifiers to patient identifiers.  This code key will 
be accessible only to study investigators and study staff.  Any hard copies of datasets will 
be stored in a locked filing cabinet.  All data collection files will be password protected and 
stored on computers belonging to study investigators.  After all data are collected, 
analyzed, and published, linkage between patients and their unique identifier will be 
destroyed, with the exception of data collected through Infection Control Departments as 
part of hospital operations.  Identified datasets related to infection control activities will be 
maintained at the primary institution according to hospital operations policy.  During the 
course of the study, information collected will not be disclosed to anyone other than the 
study personnel.  This data and research will not be used or disclosed to any persons or 
entity outside of the study institutions.   
 
2. The research cannot practicably be conducted without the waiver. Given the large 
number of subjects , the research cannot be completed easily without the waiver. Since the 
experimenntal design of the study is intending to study the effect of universal bathing on an 
intensive care unit, the inability to obtain patient specific data from even a small number of 
patients would adversely effect our ability to draw conclusions about the effect of bathing.  
Patients who do not receive the proposed intervention (chlorhexidine bathing) could serve 
as reservoirs of microorganisms that could impact transmission. 
 
3. The research could not practicably be conducted without access to and use of the 
protected health information. Accurate determination of lengths of stays and total patient 
days for all involved study participants will require access to dates of admission and 
discharge (protected health information).  Without this information the research can not be 
practically conducted.  
 
7.5 Protection Against Risk. 
The study site Principal Investigator is responsible for the preparation and submission of all 
documents and periodic reports required by the local IRB. All protocol amendments 
affecting the safety and welfare of study participants must be approved by the IRBs prior to 
implementation. All investigators and participating sites will be in full compliance with 
human subjects and HIPAA requirements. This study protocol will be submitted to the 
Centers for Disease Control for IRB approval and the CDC may defer to local center’s IRB 
for human subject research protection oversight. The sponsoring institution and 
participating institutions promise that the study will be conducted to good clinical practice 
guidelines, applicable laws and regulations, and will report to investigators and regulatory 
authorities significant findings that could affect the safety and well being of research 
subjects.  All study investigators and staff have been trained in human subjects research 
and HIPAA regulations.   
 
Monitoring of any unexpected adverse effects or serious adverse events related to study 
procedures will be the responsibility of local investigators and are to be reported 
immediately to the steering committee as well as appropriate IRB.  All unexpected adverse 
events and serious events are to be reported and sent to the steering committee at the 
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coordinating center (McGuire) within five working days on the adverse event form (see 
Appendix H.) 
 
For the purposes of this research protocol unexpected adverse events and serious adverse 
events will be defined as follows: 
 
Unexpected adverse event:  Any adverse reaction or experience that is not listed in the 
current labeling for the drug product or investigators brochure. This includes events that 
may be symptomatically and pathophysiologically related to an event listed in the labeling, 
but differ from the event because of greater severity or specificity. Known adverse reactions 
to chlorhexidene containing topical products include irritation, sensitization, and generalized 
allergic reactions especially in the genital area.  Chlorhexidine should be kept out of the 
ears and eyes.  "Unexpected," as used in this definition, refers to an adverse experience 
that has not been previously observed (i.e., included in the labeling) rather than from the 
perspective of such experience not being anticipated from the pharmacological properties 
of the pharmaceutical product. 
 
Serious adverse drug event. Any adverse reaction or experience occurring at any dose that 
results in any of the following outcomes: Death, a life-threatening adverse reaction, 
inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant 
disability/incapacity, or a congenital anomaly/birth defect. Important medical events that 
may not result in death, be life-threatening, or require hospitalization may be considered a 
serious adverse drug experience when, based upon appropriate medical judgment, they 
may jeopardize the patient or subject and may require medical or surgical intervention to 
prevent one of the outcomes listed in this definition.  
 
 
7.6 Potential Risks  
This clinical research involves minimal risk to the patients involved since it involves only the 
use of two FDA approved products.  Chlorhexidine has been widely used as a topical agent 
for skin disinfection in concentrations ranging from 0.5% to 4%.  It is used extensively for 
skin disinfection, handwashing, oral care, irrigation of surgical wounds, the urinary bladder 
or vagina, topical treatment of burn wounds, and treatment of peritonitis in peritoneal 
dialysis (47). Daily bathing with chlorhexidine has been used within the hospital 
environment as a means to disinfect the skin and decrease the transmission of nosocomial 
pathogens including MRSA and VRE (18-25, 29).  Sage 2% Chlorhexidine Gluconate 
Cloths has been shown to reduce bacteria that can potentially cause skin infection.  In 
addition, 2% Chlorhexidine Gluconate Cloths have been used as a daily bathing cloth in 
several studies and shown to be well tolerated.  In the VRE transmission study (Vernon et 
al.), 394 patients received daily bathing with the 2% Chlorhexidine Gluconate Cloth with a 
lower reported rate of skin irritation in comparison to patients who received soap and water 
bathing (29).  In the Skin Cleansing with Chlorhexidine Study (Protocol 05-006), 343 
patients have undergone daily bathing with the 2% chlorhexidine cloth with no reported 
adverse events attributable to chlorhexidine bathing (see Investigators Brochure).  No 
Serious Adverse events have been reported to date in any clinical trial involving 2% 
Chlorhexidine Gluconate Cloths. Despite the overall low rate of expected adverse events, 
several restrictions will be place for the use of the 2% Chlorhexidine Cloth.  The 2% 
Chlorhexidine cloth will not be used in the following situations: 
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1) on patients with known allergies to chlorhexidine gluconate or any other ingredients 
in the product 
2) on burn patients with a high percentage of disrupted body surface area. 
3) for lumbar punctures or in contact with the meninges, or  
4) on open skin wounds; and  
5) the product should be kept out of the eyes, ears, and mouth 
 
 
Potential recognized risks of bathing with chlorhexidine include local skin irritation, 
sensitization, allergic reaction and irritation of mucous membranes. Chlorhexidine is not to 
be used in children. This research only involves adult patients aged 18 years or older.  
7.7 Potential Benefits Of The Proposed Research To The Subjects And Others  
The intent of this study is to demonstrate that the routine use of chlorhexidine in bathing 
practices will lead to reduced skin colonization with resistant bacteria including MRSA and 
VRE.  This reduction can lead to significant declines in the incidence of MRSA and VRE 
and nosocomial bacteremias.  Such reductions could have profound effects on associated 
health care costs and mortality.  Since the intervention that is proposed is of minimal risk to 
the involved patients the potential benefits far outweigh any potential risk to individual 
patients.  
7.8 Importance Of The Knowledge To Be Gained  
MRSA and VRE are serious nosocomial pathogens associated with high morbidity and 
mortality for involved patients. In addition, nosocomial bacteremias are the leading cause of 
death among intensive care unit patients.  Novel interventions that reduce these 
complications would greatly benefit large populations within our healthcare systems. If 
changes in bathing practices prove to be effective in reducing these complications, this 
would represent a simple intervention that could be applied broadly to all hospitals.  
 
7.9 Inclusion of Women and Minorities 
 
The proposed clinical research will involve all adult patients admitted to participating units.  
There will be no exclusion of any gender, racial or ethnic minority. Racial or ethnic origin of 
patients in previous pilot studies completed to date was not accurately determined (this 
information was not collected).  This does not compromise the scientific objectives of the 
research, since the proposed intervention it is to be applied universally and race, ethnic 
origin and gender have no bearing on the intended effect.  Although exact demographics 
for the targeted study populations are not readily available, we have estimated the 
distribution of gender and racial and ethnic groups to be enrolled based on prior studies 
done in the ICU environment. 
 
7.10 Inclusion of Children 
This clinical research will involve the enrollment of children. However it will only involve 
children from the age of 18-20 and as dictated by local policies for admission to the 
participating units. All of the proposed study units currently only admit adult patients.  For 
most of the participating units this includes patients >18 years of age. Since the definition of 
children for the purpose of this application include any patient < 21 years of age, we will be 
enrolling children. 
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Apppendix B. List of Microbiologic Classification of Blood Stream Infections 
 
0
. 
NO GROWTH/ NEGATIVE 37. Corynebacterium jeikeium 74. Other (not listed elsewhere)               
1.  Achromobacter species 38. Corynebacterium, others 75. Pasteurella multocida                      
2.  Acinetobacter baumannii 39. Cryptococcus neoformans 76. Peptostreptococcus species 
3.  Acinetobacter calcoaceticus 40. Diphtheroids 77. Porphyromonas species 
4.  Acinetobacter lwoffii 41. Enterobacter aerogenes 78. Prevotella species                          
5.  Acinetobacter, others 42. Enterobacter cloacae 79. Propionibacterium species                 
6.  Actinomyces species 43. Enterobacter, others 80. Proteus mirabilis                           
7.  Aeromonas species 44. Enterococcus faecalis (vanco-
sensitive) 
81. Proteus vulgaris                            
8.  Alcaligenes species 45. Enterococcus faecalis (vanco-
resistant) 
82. Proteus, others                             
9.  Aspergillus species 46. Enterococcus faecium (vanco-
sensitive) 
83. Providencia species                         
10. Bacillus anthracis 47. Enterococcus faecium (vanco- 
resistant) 
84. Pseudomonas aeruginosa                 
11. Bacillus cereus 48. Enterococcus gallinarum 85. Pseudomonas, others                        
12. Bacillus subtilis 49. Enterococcus, others 86. Serratia marcescens                        
13. Bacillus, others 50. Escherichia coli 87. Serratia, others                            
14. Bacteroides fragilis 51. Flavobacterium species 88. Sporothrix schenckii                        
15. Bacteroides, others 52. Fungus 89. Staphylococcus aureus 
(methicillin-sensitive)                      
16. Blastomyces dermatitidis 53. Fusarium species 90. Staphylococcus aureus 
(methicillin-resistant) 
17. Branhamella catarrhalis 54. Fusobacterium species 91.
Staphylococcus capitis                   
18. Burkholderia cepacia 55. Gram-negative cocci unspecified            92. Staphylococcus coagulase 
negative           
19. Campylobacter species 56. Gram-negative rod unspecified              93. Staphylococcus 
epidermidis                  
20. Candida albicans 57. Gram-positive cocci unspecified            94. Staphylococcus 
haemolyticus                 
21. Candida glabrata 58. Gram-positive rod unspecified               95. Staphylococcus hominis                
22. Candida krusei 59. Haemophilus species                         96. Staphylococcus 
saprophiticus                
23. Candida lusitaniae 60. Histoplasma capsulatum                      97. Staphylococcus warneri                 
24. Candida parapsilosis 61. Klebsiella oxytoca                          98.
Staphylococcus, others                   
25. Candida tropicalis 62. Klebsiella pneumoniae                       99. Stenotrophomonas 
maltophilia                
26. Candida, others 63. Klebsiella, others                          100 Streptococcus group A 
(pyogenes)            
27. Citrobacter diversus 64. Lactobacillus species  101 Streptococcus group B 
(agalactiae)          
28. Citrobacter freundii 65. Listeria monocytogenes                      102 Streptococcus group D 
(bovis)               
29. Citrobacter koseri 66. Malassezia furfur                           103 Streptococcus pneumoniae 
30. Citrobacter, others 67. Microccoccus species                        104 Streptococcus viridans  
31. Clostridium difficile 68. Moraxella catarrhalis                       105 Streptococcus, alpha hem  
32. Clostridium perfringens 69. Morganella morganii                         106 Streptococcus, beta hem  
33. Clostridium, others 70. Neisseria gonorrhoeae 107 Streptococcus, others  
34. Coagulase negative staph 
(CNS) 
71. Neisseria meningiditis                           108 Torulopsis glabrata 
35. Coccidioides immitis 72. Neisseria, others 109 Yeast 
36. Corynebacterium group G-2 73. Nocardia species   
 
Note: Underlined organisms represent common skin contaminants for the purpose of assigning 
a BSI classification. Organisms in bold represent coagulase-negative staphylococcus species 
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Appendix C. Definitions of all Entry fields in Access Database 
 
Demographics Form 
 
1. Epicenter:  Drop list for participating centers in study 
 
2. Start Date:  Starting date of study period 
 
3. End Date:  Last date of study period 
 
4. Study ID: sequential ID number given to study patients 
 
5. MRN: Medical record of study patient used during data entry for tracking and 
accuracy.  Field is removed prior to data submission to coordinating center 
 
6. Last Name: Last name of study patient used during data entry for tracking and 
accuracy.  Field is removed prior to data submission to coordinating center 
 
7. First name: First name of study patient used during data entry for tracking and 
accuracy.  Field is removed prior to data submission to coordinating center 
 
8. Gender:  Gender of study participant 
 
9. First MRSA Institutional Culture Date: Date of the first recorded positive culture for 
MRSA at the institution for the study participant 
 
10. First VRE Institutional Culture Date: Date of the first recorded positive culture for 
VRE at the institution for the study participant 
 
11. Age at First Unit Admit:  Age of the study participant at the time of unit admission.  
Age is chosen from drop down list that is listed in decades; 1) <18, 2) 18-35, 3) 36-45, 
4) 46-55, 5) 56-65, 6) 66-75, 7) 76-85, and 8) >85. 
 
Unit Subform 
 
12.   UnitID:  Numbering system for ICU admissions, each admission is given a unique unit 
ID number,  all study ID are patient specific and thus each study ID may have multiple 
unit ID numbers.  Autonumbered on Dataview sheet. 
 
13.   Unit name:  Name of study unit, up to two units in study per participating institution 
 
14. Unit Admit Date:  Date of admission to study unit 
 
15.   Unit Discharge date:  Date of discharge from study unit 
 
16.   Study ID: Sequential ID number given to study patients 
 
17. Mupirocin during Admit:  Was patient placed on mupirocin during any portion of the 
admission, (yes or no, checkbox) 
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18. Cultures Prior to Unit Admission: Were there cultures for MRSA or VRE present prior 
to admission to study unit (present or none)? Present prompts entry into Pre-Admit 
Cultures subform 
 
19. Cultures During to Unit Admission:  Were there any cultures taken during study unit 
admission (none or present)? Cultures include any cultures positive for MRSA, VRE and 
all positive blood cultures. Present prompts entry into Cultures subform 
 
 
Pre-Admit culture form 
 
 
20. Specimen Site: Site of most recent MRSA or VRE culture prior to admission 
 
21. Specimen__Date:  Date of most recent MRSA or VRE culture prior to admission 
 
22. MRSA Result:  Result of most recent MRSA culture prior to admission (yes, no, not 
eval) 
 
23. VRE Result  Result of most recent VRE culture prior to admission (yes, no, not eval) 
 
24. Organism:  MRSA or VRE, on this form should only reflect results of MRSA and VRE 
culturing prior to admission. 
 
25. StudyID:  Sequential ID number given to study patients generated on demographics 
form. 
 
Cultures subform 
 
26. Specimen Site: Site of MRSA or VRE culture during study unit admission.  Data on all 
blood cultures is also entered into this field by selecting blood culture as specimen site. 
 
27. Specimen__Date:  Date of MRSA or VRE culture during study unit admission 
 
28. MRSA Result:  Result of MRSA culture during study unit admission (yes, no, not eval) 
 
29. VRE Result  Result of VRE culture during study unit admission (yes, no, not eval) 
 
30. Organism:  MRSA or VRE, on this form should only reflect results of MRSA and VRE 
culturing during study unit admission. 
 
31. StudyID:  Sequential ID number given to study patients generated on demographics 
form. 
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Appendix D.  SAGE Products, Inc. Comfort Bath® Product Brochure 
 
 Page39 
 
 Page40 
 
 Page41 
 
 Page42 
Appendix E.  SAGE Products, Inc. Chlorhexidine Impregnated Washcloth Product Brochure 
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Appendix F. MSDS - Comfort Bath® Wash cloth  
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Appendix G.  MSDS - 2% Chlorhexidine Gluconate Cloth 
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 ADVERSE EVENT SUBMISSION FORM 
Date:  
Principal Investigator, Sponsor:  Climo, Michael 
Protocol#:  CI06-003 
Protocol Title:  Multicenter Evaluation of The Effectiveness of Source Control With Daily Chlorhexidine Skin 
Preparation in Reducing Nosocomial Infections Including MRSA and VRE 
 
Funding:  SAGE Products, Inc., and Center for Disease Control and Prevention 
Research Coordinator(s): 
 
Phone: 
 
Fax: 
 
 
Report Type:   Initial     Follow-up 
Subject Identifier # (study ID number, do not list medical record number or other personal identifier): 
AE Date:   
AE Description (brief):   
 
 
 
 
 
 
 
 
 
Is the adverse event a previously described complication that is listed in the “Risk” section of the Investigator’s 
Brochure   Yes     No 
 
This is a (an):  
 
 Unanticipated/Unexpected Event  
(Any untoward event that is not identified with the 
current investigator brochure or study protocol) 
 
 Serious Adverse Event  
(Any untoward medical occurrence that results in 
death, is life-threatening, requires patient 
hospitalization, prolongs existing hospitalization, 
results in persistent or significant 
disability/incapacity, or is a congenital 
abnormality) 
 
The opinion of the Principal Investigator is that the 
relationship of the research procedure is: 
 
Unrelated 
Probably not related 
Possibly related 
Probably related 
Related 
Other:       
 
 
 
The Principal Investigator must promptly report to the IRB, in writing, any unanticipated side effects, hazards, 
or other problems involving risks to subjects or others.   Promptly report all adverse events considered to be 
related to research procedures to the Steering Committee. 
 
________________________________________          _________________ 
INVESTIGATOR SIGNATURE          DATE 
(Sub-investigator may sign if the investigator is unavailable (i.e. out of the country) 
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Appendix I.  Example of Patient Information Sheet 
 
XXXXXXXXXXXXXXX Medical Center 
SUBJECT INFORMATION SHEET 
 
“Multicenter Evaluation of the Effectiveness of Source Control with Daily Chlorhexidine Skin 
Preparation in Reducing Nosocomial Infections Including MRSA and VRE” 
 
We are trying to learn whether the ways that patients are bathed can affect their risk of acquiring infections in 
the intensive care unit.  We are especially interested in knowing if a new bath procedure will reduce the 
number of harmful bacteria on your skin and lower your risk of infection.  
 
The Comfort Bath Cleansing System from Sage Products Inc. is one way that patients can be bathed.  The 
Comfort Bath Cleansing System has been available since 1999.  It is used in 20% of US hospitals.  The 
Comfort Bath System, as shown in the picture below, contains eight disposable washcloths, premoistened with 
a rinse-free cleansing and moisturizing solution.  
              
   
 
The bath procedure involves warming the packet and using one washcloth at a time to clean each separate 
body part. You will be bathed with this product or with a new version of the Comfort Bath System that contains 
2% chlorhexidine gluconate (CHG), as shown in the picture above. CHG is an antiseptic agent that has been 
used for skin cleansing for many years. It is used routinely in hospitals to clean skin before surgery and is 
available over-the-counter at your local drugstore.  The use of CHG in the Comfort Bath System for patient 
bathing has been studied at other hospitals under the supervision of the FDA but during this study will (1)  be 
used in an experimental manner, as it is not currently approved as a general skin cleanser; (2) may cause 
potential adverse experiences, such as skin irritation, sensitization, and generalized allergic reactions; (3) that 
the 2% Chlorhexidine Gluconate* Cloth should not be used: (a) on patients with known allergies to 
chlorhexidine gluconate or any other ingredients in the product, (b) for lumbar punctures or in contact with the 
meninges, or (c) on open skin wounds; and (4) the product should be kept out of the eyes, ears, and mouth. 
 
The Comfort Bath System is provided to you by the manufacturer at no charge.  You will not be charged for the 
product. 
 
If you have a question about this information, you may call Dr. XXXX XXXX at (XXX) XXX-XXXX or Mr. XXXX 
XXXX, R.N. at (XXX) XXX-XXXX. 
 
Summary of Protocol Changes from version 1.0 to version 1.3 
1. Section 6.5 (page 13) was amended to indicate that skin care moisturizers 
compatible with the use of chlorhexidine would be utilized by all study units as 
follows: 
“Many skin care moisturizers that contain anionic emulsifiers may adversely affect the residual 
antibacterial effect of chlorhexidine and should be avoided during routine care during periods in which 
chlorhexidine is in use.  Skin care products that are known to be compatible with chlorhexidine 
include: Aquaphor® Original Formula Ointment, Lubriderm® Dry Skin Care Lotion, Eucerin® Original 
Lotion, Vaseline® 100% Pure Petroleum Jelly, PROVON® Moisturizing Lotion.  Participating study 
units will be asked to utilize one of these products for skin care during the proposed study.” 
 
2. Section 6.76 Mupirocin Use was added on page 16.   
 
“Each Study patient will have information about the concurrent use of mupirocin use during the 
admission recorded.  This information is being collected to determine if concurrent mupirocin use 
affects the clearance of MRSA from the study population.  Use of any mupirocin during the admission 
will be recorded in the Access Database.” 
 
3. Section 7.3 (page 25) was changed to indicate that the trial would be conducted with 
waiver of documentation of written informed consent instead of waiver of informed 
consent.  
“This study will involve all adult patients admitted to the proposed study units. As such there is no 
recruitment strategy. It is intended to encompass all patients within the participating units. This study 
will be seeking waiver of documentation of written informed consent in accordance with 21 CFR 
56.109(c): 
“An IRB shall require documentation of informed consent in accordance with Sec. 50.27 of this 
chapter, except as follows: (1) The IRB may, for some or all subjects, waive the requirement that the 
subject, or the subject's legally authorized representative, sign a written consent form if it finds that 
the research presents no more than minimal risk of harm to subjects and involves no procedures for 
which written consent is normally required outside the research context; or (2) The IRB may, for some 
or all subjects, find that the requirements in Sec. 50.24 of this chapter for an exception from informed 
consent for emergency research are met.”  
1. The intended research presents no more than minimal risk to the patients.  The intent is to study 
the potential differences between two accepted bathing products for patients and to determine if there 
is the potential to reduce nosocomial infections.  Both products are FDA approved products and as 
such pose minimal risk to those patients involved.  Bathing with chlorhexidine is an accepted 
procedure within the hospital and is often applied to selected patient populations within the hospital 
including pre-operative patients.    
 
2. The activities within the proposal do not normally require informed consent. Bathing is an accepted 
practice within the hospital and does not require written informed consent.  Surveillance cultures are 
normally done in the course of many hospital surveillance activities and the standard of care is to 
require only verbal permission prior to collection.   
 
In accordance with 45 CFR 56.109(d), subjects in the trial will be given a written statement about the 
nature of the study. 
“(d) In cases where the documentation requirement is waived under paragraph (c)(1) of this section, 
the IRB may require the investigator to provide subjects with a written statement regarding the 
research. “ 
An example of the patient information sheet is included in Appendix I. “ 
4. Section 7.4 (page 26) was amended to include a more detailed explanation of the 
rationale for a waiver of HIPAA authorization as follows: 
“Since the experimenntal design of the study is intending to study the effect of universal bathing on an 
intensive care unit, the inability to obtain patient specific data from even a small number of patients 
would adversely effect our ability to draw conclusions about the effect of bathing.  Patients who do not 
receive the proposed intervention (chlorhexidine bathing) could serve as reservoirs of 
microorganisms that could impact transmission.” 
 
5. Section 7.6 (page 27) was ammended with a more detailed description of the known 
adverse reactions to the topical use of chlorhexidine and exclusions to its use as 
follows: 
 
“Chlorhexidine has been widely used as a topical agent for skin disinfection in concentrations ranging 
from 0.5% to 4%.  It is used extensively for skin disinfection, handwashing, oral care, irrigation of 
surgical wounds, the urinary bladder or vagina, topical treatment of burn wounds, and treatment of 
peritonitis in peritoneal dialysis (47). Daily bathing with chlorhexidine has been used within the 
hospital environment as a means to disinfect the skin and decrease the transmission of nosocomial 
pathogens including MRSA and VRE (18-25, 29).  Sage 2% Chlorhexidine Gluconate Cloths has 
been shown to reduce bacteria that can potentially cause skin infection.  In addition, 2% 
Chlorhexidine Gluconate Cloths have been used as a daily bathing cloth in several studies and 
shown to be well tolerated.  In the VRE transmission study (Vernon et al.), 394 patients received daily 
bathing with the 2% Chlorhexidine Gluconate Cloth with a lower reported rate of skin irritation in 
comparison to patients who received soap and water bathing (29).  In the Skin Cleansing with 
Chlorhexidine Study (Protocol 05-006), 343 patients have undergone daily bathing with the 2% 
chlorhexidine cloth with no reported adverse events attributable to chlorhexidine bathing (see 
Investigators Brochure).  No Serious Adverse events have been reported to date in any clinical trial 
involving 2% Chlorhexidine Gluconate Cloths. Despite the overall low rate of expected adverse 
events, several restrictions will be place for the use of the 2% Chlorhexidine Cloth.  The 2% 
Chlorhexidine cloth will not be used in the following situations: 
  
1) on patients with known allergies to chlorhexidine gluconate or any other ingredients in the 
product 
2) on burn patients with a high percentage of disrupted body surface area. 
3) for lumbar punctures or in contact with the meninges, or  
4) on open skin wounds; and  
5) the product should be kept out of the eyes, ears, and mouth 
 
Potential recognized risks of bathing with chlorhexidine include local skin irritation, sensitization... “ 
6. Page 31. The following reference was added, “Kaul, A.F. and Jewett, J.F. Agents 
and Techniques for disinfection of the skin.  Surgery, Gynecology, and Obstetrics, 
1981, 152:677-684.” 
 
7. Appendix I “Example of Patient Information Sheet” was added on page 53. 
 
8. Minor spelling and formatting changes were made throughout the protocol. 
Initial Statistical Analysis Plan  
 
The effect of daily bathing with chlorhexidine impregnated washcloths on 
incidence density of BSI, MRSA, and VRE incidence will be modeled by means of 
Generalized Estimating Equations (GEEs) under the Poisson distribution family.  Since 
each unit is observed twice under the study’s crossover design (once under the 
experimental and once under the control condition) and the targeted outcome is in the 
form of counts (here new cases or infections related to patient days of exposure), the 
GEE methodology is needed to model the count outcomes while accounting for the 
natural clustering effects induced by repeated observation of units.   
Our study design requires three separate analyses based upon the type of 
surveillance (MRSA only, VRE only, or both) employed by the units.  The analysis of 
BSI rates will use data from all units and will incorporate a three level fixed effect 
designating surveillance type.  The analyses of MRSA and VRE rates, respectively, will 
be based on only those units engaging in the corresponding type of surveillance.  In the 
latter analyses, a two level fixed effect for surveillance type will be incorporated (MRSA 
only versus both - or VRE only versus both).  
The fundamental model in these analyses will specify treatment, order of 
presentation, and type of surveillance fixed main effects.   Offsets in each model will be 
unit specific total patient days during the exposure periods.  Even though the study 
design targets minimizing order and type of surveillance effects and neither are 
expected to be present in any magnitude, their possible effects will be incorporated for 
control purposes.  If either proves to be significant, their interactive effects with 
treatment will also be examined.  Such interactive effects are likewise not expected to 
be present. 
 All significance tests in these analyses will be conducted given two-tailed alpha of 
.05.  In addition, 95% confidence intervals estimating treatment and control rates as well 
as their ratio will be constructed.  It should be noted that in this study, there can be no 
missing data and consequently no missing data issues.  Analyses are planned to be 
conducted using the SAS software for Windows (Version 9.1.3 or later). 
 
 
Final Statistical Analysis Plan 
We evaluated changes in the mean incidence of MRSA and VRE acquisition and 
the development of bloodstream infections using a Poisson regression model that 
included consideration of the prevalence of MRSA and VRE as a confounder. We tested 
the null hypothesis that the incidence rate during the baseline period equals the incident 
rate during the intervention period using PROC GENMOD in SAS (version 9.2, Cary, 
NC) to fit a Poisson regression model.  Modeling included considerations of the monthly 
prevalence of MRSA and VRE in the comparison to exclude the possibility that 
observed reductions in incidence were associated with clustering of MRSA and or VRE.  
The monthly prevalence was calculated as the proportion of admitted patients with 
prevalent cases of MRSA or VRE on admission to study units compared to the total 
number of patients.  
 The Cox proportional-hazards regression model was used to compare the 
differences in the time to development of incident primary bloodstream infections 
between the control group and the intervention group (chlorhexidine bathing).  For the 
model, the survival time was calculated as 1) the interval between admission and 
discharge from the study unit for those patients with no diagnosis of incident primary 
bloodstream infection and as 2) the interval between admission and the first positive 
culture for patients diagnosed with primary bloodstream infections. 
 Characteristics of individual units examined to determine if they influenced 
observed reduction in primary bloodstream infection included unit size, unit type, 
observed length of stay, use of central venous catheters, median age of patients, 
gender of patients, baseline primary BSI rate, baseline incident MRSA rate, baseline 
incident VRE rate, prevalence of MRSA, and prevalence of VRE.  We compared 
changes in the mean incidence of primary bloodstream infections between the control 
period and intervention periods. Continuous variables were examined by two sample t 
test and linear regression modeling.  Categorical variables were examined by Fisher 
exact test. 
 
Summary of Changes to Statistical Analysis Plan 
 
1. The final Poison Regression modeling included considerations of the monthly 
prevalence of MRSA and VRE in the comparison to exclude the possibility that 
observed reductions in incidence were associated with clustering of MRSA and or 
VRE. 
2. The final Poison Regression model did not incorporate a three level fixed effect 
designating surveillance type since all participating units performed surveillance for 
both MRSA and VRE. 
3. The final statistical analysis included the Cox proportional-hazards regression model 
to compare the differences in the time to development of incident primary 
bloodstream infections. 
